DK2015758T3 - Forbindelser og fremgangsmåder til modulering af ekspression af apob - Google Patents
Forbindelser og fremgangsmåder til modulering af ekspression af apobInfo
- Publication number
- DK2015758T3 DK2015758T3 DK07811873.4T DK07811873T DK2015758T3 DK 2015758 T3 DK2015758 T3 DK 2015758T3 DK 07811873 T DK07811873 T DK 07811873T DK 2015758 T3 DK2015758 T3 DK 2015758T3
- Authority
- DK
- Denmark
- Prior art keywords
- short antisense
- antisense compounds
- compounds
- reduction
- monomers
- Prior art date
Links
- 102100040202 Apolipoprotein B-100 Human genes 0.000 title 1
- 101000889953 Homo sapiens Apolipoprotein B-100 Proteins 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 7
- 230000000692 anti-sense effect Effects 0.000 abstract 6
- 239000000178 monomer Substances 0.000 abstract 2
- 241001465754 Metazoa Species 0.000 abstract 1
- 108091005461 Nucleic proteins Proteins 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 230000004048 modification Effects 0.000 abstract 1
- 238000012986 modification Methods 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 239000002773 nucleotide Substances 0.000 abstract 1
- 125000003729 nucleotide group Chemical group 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 231100001274 therapeutic index Toxicity 0.000 abstract 1
- 230000001988 toxicity Effects 0.000 abstract 1
- 231100000419 toxicity Toxicity 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y203/00—Acyltransferases (2.3)
- C12Y203/01—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
- C12Y203/0102—Diacylglycerol O-acyltransferase (2.3.1.20)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/322—2'-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/341—Gapmers, i.e. of the type ===---===
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3515—Lipophilic moiety, e.g. cholesterol
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Virology (AREA)
- Emergency Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Gastroenterology & Hepatology (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US74663106P | 2006-05-05 | 2006-05-05 | |
| US74705906P | 2006-05-11 | 2006-05-11 | |
| US80566006P | 2006-06-23 | 2006-06-23 | |
| US86455406P | 2006-11-06 | 2006-11-06 | |
| PCT/US2007/061183 WO2007090071A2 (en) | 2006-01-27 | 2007-01-27 | 6-modified bicyclic nucleic acid analogs |
| PCT/US2007/068403 WO2007131238A2 (en) | 2006-05-05 | 2007-05-07 | Compounds and methods for modulating expression apob |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2015758T3 true DK2015758T3 (da) | 2014-06-23 |
Family
ID=40134111
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK07811873.4T DK2015758T3 (da) | 2006-05-05 | 2007-05-07 | Forbindelser og fremgangsmåder til modulering af ekspression af apob |
| DK07811878.3T DK2019692T3 (da) | 2006-05-05 | 2007-05-07 | Forbindelser og fremgangsmåder til modulation af ekspression af gccr |
| DK11160528.3T DK2363481T3 (en) | 2006-05-05 | 2007-05-07 | Compounds and methods for modulating gene expression |
| DK07811872.6T DK2021472T3 (da) | 2006-05-05 | 2007-05-07 | Forbindelser og fremgangsmåder til modulering af genekspression |
| DK11189591.8T DK2458006T3 (en) | 2006-05-05 | 2007-05-07 | Compounds and Methods for Modulating ApoB Expression. |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK07811878.3T DK2019692T3 (da) | 2006-05-05 | 2007-05-07 | Forbindelser og fremgangsmåder til modulation af ekspression af gccr |
| DK11160528.3T DK2363481T3 (en) | 2006-05-05 | 2007-05-07 | Compounds and methods for modulating gene expression |
| DK07811872.6T DK2021472T3 (da) | 2006-05-05 | 2007-05-07 | Forbindelser og fremgangsmåder til modulering af genekspression |
| DK11189591.8T DK2458006T3 (en) | 2006-05-05 | 2007-05-07 | Compounds and Methods for Modulating ApoB Expression. |
Country Status (15)
| Country | Link |
|---|---|
| US (14) | US20090292006A1 (cg-RX-API-DMAC7.html) |
| EP (10) | EP2015758B1 (cg-RX-API-DMAC7.html) |
| JP (7) | JP2009536039A (cg-RX-API-DMAC7.html) |
| KR (1) | KR101441700B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN103554205A (cg-RX-API-DMAC7.html) |
| AT (2) | ATE514777T1 (cg-RX-API-DMAC7.html) |
| AU (4) | AU2007257094B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BRPI0711429A2 (cg-RX-API-DMAC7.html) |
| CA (3) | CA2651309C (cg-RX-API-DMAC7.html) |
| DK (5) | DK2015758T3 (cg-RX-API-DMAC7.html) |
| ES (2) | ES2471978T3 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2008014100A (cg-RX-API-DMAC7.html) |
| NO (1) | NO20084738L (cg-RX-API-DMAC7.html) |
| PT (1) | PT2015758E (cg-RX-API-DMAC7.html) |
| WO (9) | WO2007146511A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (384)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7407943B2 (en) | 2001-08-01 | 2008-08-05 | Isis Pharmaceuticals, Inc. | Antisense modulation of apolipoprotein B expression |
| US20060009410A1 (en) * | 2002-11-13 | 2006-01-12 | Crooke Rosanne M | Effects of apolipoprotein B inhibition on gene expression profiles in animals |
| US7511131B2 (en) | 2002-11-13 | 2009-03-31 | Genzyme Corporation | Antisense modulation of apolipoprotein B expression |
| JP2005244488A (ja) | 2004-02-25 | 2005-09-08 | Matsushita Electric Ind Co Ltd | 複合機 |
| US20050287558A1 (en) | 2004-05-05 | 2005-12-29 | Crooke Rosanne M | SNPs of apolipoprotein B and modulation of their expression |
| US20070087987A1 (en) * | 2005-09-19 | 2007-04-19 | Monia Brett P | Modulation of glucagon receptor expression |
| EP1976567B1 (en) | 2005-12-28 | 2020-05-13 | The Scripps Research Institute | Natural antisense and non-coding rna transcripts as drug targets |
| US7764650B2 (en) | 2006-03-02 | 2010-07-27 | Intel Corporation | Mobile station and method for fast roaming with integrity protection and source authentication using a common protocol |
| NZ571569A (en) | 2006-04-03 | 2011-09-30 | Santaris Pharma As | Pharmaceutical compositions comprising anti miRNA antisense oligonucleotides |
| EP2007889A2 (en) | 2006-04-03 | 2008-12-31 | Santaris Pharma A/S | Pharmaceutical compositions comprising anti-mirna antisense oligonucleotides |
| US20090292006A1 (en) * | 2006-05-05 | 2009-11-26 | Sanjay Bhanot | Compounds and methods for modulating expression of dgat2 |
| CA2658183A1 (en) * | 2006-07-17 | 2008-01-24 | Sirna Therapeutics Inc. | Rna interference mediated inhibition of proprotein convertase subtilisin kexin 9 (pcsk9) gene expression using short interfering nucleic acid (sina) |
| WO2008049085A1 (en) | 2006-10-18 | 2008-04-24 | Isis Pharmaceuticals, Inc. | Antisense compounds |
| US8084437B2 (en) | 2006-11-27 | 2011-12-27 | Isis Pharmaceuticals, Inc. | Methods for treating hypercholesterolemia |
| US8093222B2 (en) | 2006-11-27 | 2012-01-10 | Isis Pharmaceuticals, Inc. | Methods for treating hypercholesterolemia |
| CA2681406A1 (en) * | 2007-03-22 | 2008-09-25 | Santaris Pharma A/S | Rna antagonist compounds for the inhibition of apo-b100 expression |
| JP2010522245A (ja) | 2007-03-24 | 2010-07-01 | ゲンザイム コーポレイション | ヒトアポリポタンパク質ｂと相補的なアンチセンスオリゴヌクレオチドの投与 |
| KR20100024399A (ko) | 2007-05-01 | 2010-03-05 | 엔즌 파마슈티칼스, 인코포레이티드 | 베타-카테닌의 조절용 ｒｎａ 길항제 화합물 |
| MX2009012271A (es) | 2007-05-11 | 2010-02-04 | Enzon Pharmaceuticals Inc | Compuestos antagonistas de acido ribonucleico para la modulacion de her3. |
| ES2376507T5 (es) † | 2007-07-05 | 2015-08-31 | Isis Pharmaceuticals, Inc. | Análogos de ácidos nucleicos bicíclicos 6-disustituidos |
| EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| MX2010003299A (es) | 2007-10-04 | 2010-04-14 | Santaris Pharma As | Oligonucleotidos muy cortos (micromirs). |
| WO2009046426A2 (en) * | 2007-10-04 | 2009-04-09 | Isis Pharmaceuticals, Inc. | Compounds and methods for improving cellular uptake of oligomeric compounds |
| MX2010005703A (es) | 2007-11-26 | 2010-06-11 | Enzon Pharmaceuticals Inc | Antagonistas de acido nucleico entrelazado que eligen como objetivo al receptor de androgeno. |
| US8450290B2 (en) | 2007-11-26 | 2013-05-28 | Enzon Pharmaceuticals, Inc. | Methods for treating androgen receptor dependent disorders including cancers |
| EP2238249A2 (en) * | 2007-12-07 | 2010-10-13 | Santaris Pharma A/S | Rna antagonist compounds for the modulation of mcl-1 |
| US10131904B2 (en) | 2008-02-11 | 2018-11-20 | Rxi Pharmaceuticals Corporation | Modified RNAi polynucleotides and uses thereof |
| CA2717792A1 (en) | 2008-03-07 | 2009-09-11 | Santaris Pharma A/S | Pharmaceutical compositions for treatment of microrna related diseases |
| WO2009117589A1 (en) | 2008-03-21 | 2009-09-24 | Isis Pharmaceuticals, Inc. | Oligomeric compounds comprising tricyclic nucleosides and methods for their use |
| EP2274423A2 (en) | 2008-04-04 | 2011-01-19 | Isis Pharmaceuticals, Inc. | Oligomeric compounds comprising bicyclic nucleosides and having reduced toxicity |
| WO2009127680A1 (en) * | 2008-04-16 | 2009-10-22 | Santaris Pharma A/S | Pharmaceutical composition comprising anti pcsk9 oligomers |
| WO2009143390A2 (en) | 2008-05-22 | 2009-11-26 | Isis Pharmaceuticals, Inc. | Methods for modulating expression of rbp4 |
| WO2009148605A2 (en) * | 2008-06-04 | 2009-12-10 | Isis Pharmaceuticals, Inc. | Methods for treating hypercholesterolemia |
| WO2009149182A1 (en) | 2008-06-04 | 2009-12-10 | The Board Of Regents Of The University Of Texas System | Modulation of gene expression through endogenous small rna targeting of gene promoters |
| AU2009276763B2 (en) | 2008-07-29 | 2015-07-16 | The Board Of Regents Of The University Of Texas Sytem | Selective inhibition of polyglutamine protein expression |
| EP2315832B1 (en) | 2008-08-01 | 2015-04-08 | Roche Innovation Center Copenhagen A/S | Micro-rna mediated modulation of colony stimulating factors |
| EP2334319B1 (en) | 2008-08-25 | 2017-12-06 | Excaliard Pharmaceuticals, Inc. | Method for reducing scarring during wound healing using antisense compounds directed to ctgf |
| KR101877698B1 (ko) | 2008-08-25 | 2018-07-12 | 엑스칼리아드 파마슈티컬즈, 인코포레이티드 | 결합 조직 성장 인자에 대한 안티센스 올리고뉴클레오타이드 및 그의 용도 |
| US8664189B2 (en) | 2008-09-22 | 2014-03-04 | Rxi Pharmaceuticals Corporation | RNA interference in skin indications |
| MY188457A (en) | 2008-10-03 | 2021-12-10 | Opko Curna Llc | Treatment of apolipoprotein-a1 related diseases by inhibition of natural antisense transcript to apolipoprotein-a1 |
| CA2740785C (en) | 2008-10-15 | 2017-06-20 | Isis Pharmaceuticals, Inc. | Modulation of factor 11 expression |
| WO2010048552A2 (en) * | 2008-10-24 | 2010-04-29 | Isis Pharmaceuticals, Inc. | Methods of using oligomeric compounds comprising 2'-substituted nucleosides |
| CN102282155B (zh) | 2008-12-02 | 2017-06-09 | 日本波涛生命科学公司 | 磷原子修饰的核酸的合成方法 |
| CA2745811C (en) | 2008-12-04 | 2021-07-13 | Joseph Collard | Treatment of tumor suppressor gene related diseases by inhibition of natural antisense transcript to the gene |
| RU2620970C2 (ru) | 2008-12-04 | 2017-05-30 | КьюРНА,Инк., | Лечение связанных с эритропоэтином (еро) заболеваний путем ингибирования природного антисмыслового транскрипта к еро |
| US8927511B2 (en) | 2008-12-04 | 2015-01-06 | Curna, Inc. | Treatment of vascular endothelial growth factor (VEGF) related diseases by inhibition of natural antisense transcript to VEGF |
| JO3672B1 (ar) | 2008-12-15 | 2020-08-27 | Regeneron Pharma | أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9). |
| US20130064834A1 (en) | 2008-12-15 | 2013-03-14 | Regeneron Pharmaceuticals, Inc. | Methods for treating hypercholesterolemia using antibodies to pcsk9 |
| US9493774B2 (en) | 2009-01-05 | 2016-11-15 | Rxi Pharmaceuticals Corporation | Inhibition of PCSK9 through RNAi |
| AU2010211133A1 (en) * | 2009-02-03 | 2011-07-21 | F. Hoffmann-La Roche Ag | Compositions and methods for inhibiting expression of PTP1B genes |
| WO2010090762A1 (en) | 2009-02-04 | 2010-08-12 | Rxi Pharmaceuticals Corporation | Rna duplexes with single stranded phosphorothioate nucleotide regions for additional functionality |
| CA2752239C (en) * | 2009-02-12 | 2021-03-30 | Opko Curna, Llc | Treatment of glial cell derived neurotrophic factor (gdnf) related diseases by inhibition of natural antisense transcript to gdnf |
| US9074210B2 (en) | 2009-02-12 | 2015-07-07 | Curna, Inc. | Treatment of brain derived neurotrophic factor (BDNF) related diseases by inhibition of natural antisense transcript to BDNF |
| CA2755409C (en) * | 2009-03-16 | 2019-04-30 | Joseph Collard | Treatment of nuclear factor (erythroid-derived 2)-like 2 (nrf2) related diseases by inhibition of natural antisense transcript to nrf2 |
| EP2408796B1 (en) | 2009-03-16 | 2020-04-22 | Ionis Pharmaceuticals, Inc. | Targeting Apolipoprotein B for the reduction of Apolipoprotein C-III |
| US9708604B2 (en) | 2009-03-17 | 2017-07-18 | Curna, Inc. | Treatment of delta-like 1 homolog (DLK1) related diseases by inhibition of natural antisense transcript to DLK1 |
| WO2010122538A1 (en) | 2009-04-24 | 2010-10-28 | Santaris Pharma A/S | Pharmaceutical compositions for treatment of hcv patients that are non-responders to interferon |
| WO2010124231A2 (en) | 2009-04-24 | 2010-10-28 | The Board Of Regents Of The University Of Texas System | Modulation of gene expression using oligomers that target gene regions downstream of 3' untranslated regions |
| US9155754B2 (en) | 2009-05-06 | 2015-10-13 | Curna, Inc. | Treatment of ABCA1 gene related diseases by inhibition of a natural antisense transcript to ABCA1 |
| EP2427552B1 (en) | 2009-05-06 | 2016-11-16 | CuRNA, Inc. | Treatment of tristetraproline (ttp) related diseases by inhibition of natural antisense transcript to ttp |
| JP5931720B2 (ja) | 2009-05-08 | 2016-06-08 | クルナ・インコーポレーテッド | Ｄｍｄファミリーに対する天然アンチセンス転写物の抑制によるジストロフィンファミリー関連疾患の治療 |
| KR20120069610A (ko) * | 2009-05-15 | 2012-06-28 | 에프. 호프만-라 로슈 아게 | 글루코코르티코이드 수용체(ｇｃｒ) 유전자의 발현을 억제하는 조성물 및 방법 |
| KR101749356B1 (ko) | 2009-05-18 | 2017-07-06 | 큐알엔에이, 인크. | 재편성 인자에 대한 천연 안티센스 전사체의 억제에 의한 재편성 인자 관련된 질환의 치료 |
| CN102549158B (zh) | 2009-05-22 | 2017-09-26 | 库尔纳公司 | 通过抑制针对转录因子e3(tfe3)的天然反义转录物来治疗tfe3和胰岛素受体底物蛋白2(irs2)相关的疾病 |
| KR20120024819A (ko) | 2009-05-28 | 2012-03-14 | 오피케이오 큐알엔에이, 엘엘씨 | 항바이러스 유전자에 대한 천연 안티센스 전사체의 억제에 의한 트리스테트라프롤린 관련된 질환의 치료 |
| ES2629339T3 (es) | 2009-06-16 | 2017-08-08 | Curna, Inc. | Tratamiento de enfermedades relacionadas con la paraoxonasa 1 (pon1) por inhibición de transcrito antisentido natural a pon1 |
| JP5944311B2 (ja) | 2009-06-16 | 2016-07-05 | クルナ・インコーポレーテッド | コラーゲン遺伝子に対する天然アンチセンス転写物の抑制によるコラーゲン遺伝子関連疾患の治療 |
| WO2010151671A2 (en) | 2009-06-24 | 2010-12-29 | Curna, Inc. | Treatment of tumor necrosis factor receptor 2 (tnfr2) related diseases by inhibition of natural antisense transcript to tnfr2 |
| JP5907866B2 (ja) | 2009-06-26 | 2016-04-26 | クルナ・インコーポレーテッド | ダウン症候群遺伝子に対する天然アンチセンス転写物の抑制によるダウン症候群遺伝子関連疾患の治療 |
| BR112012000828A8 (pt) | 2009-07-06 | 2017-10-10 | Ontorii Inc | Novas pró-drogas de ácido nucleico e métodos de uso das mesmas |
| EP2456870A1 (en) | 2009-07-21 | 2012-05-30 | Santaris Pharma A/S | Antisense oligomers targeting pcsk9 |
| CN102712925B (zh) | 2009-07-24 | 2017-10-27 | 库尔纳公司 | 通过抑制sirtuin(sirt)的天然反义转录物来治疗sirtuin(sirt)相关性疾病 |
| CN102762731B (zh) | 2009-08-05 | 2018-06-22 | 库尔纳公司 | 通过抑制针对胰岛素基因(ins)的天然反义转录物来治疗胰岛素基因(ins)相关的疾病 |
| US9044493B2 (en) | 2009-08-11 | 2015-06-02 | Curna, Inc. | Treatment of Adiponectin related diseases by inhibition of natural antisense transcript to an Adiponectin |
| US8791087B2 (en) | 2009-08-21 | 2014-07-29 | Curna, Inc. | Treatment of ‘C terminus of HSP70-interacting protein’ (CHIP)related diseases by inhibition of natural antisense transcript to CHIP |
| WO2011031482A2 (en) | 2009-08-25 | 2011-03-17 | Curna, Inc. | Treatment of 'iq motif containing gtpase activating protein' (iqgap) related diseases by inhibition of natural antisense transcript to iqgap |
| JP6175236B2 (ja) | 2009-09-25 | 2017-08-09 | カッパーアールエヌエー，インコーポレイテッド | フィラグリン（ｆｌｇ）の発現および活性の調整によるｆｌｇ関連疾患の処置 |
| US20120270929A1 (en) * | 2009-09-25 | 2012-10-25 | Isis Pharmaceuticals, Inc. | Modulation of ttc39 expression to increase hdl |
| EP2488210A4 (en) | 2009-10-12 | 2014-04-30 | Smith Holdings Llc | METHODS AND COMPOSITIONS FOR MODULATING GENE EXPRESSION USING IN VITO OR IN VITRO-ADMINISTERED OLIGONUCLEOTIDE MEDICAMENTS |
| AU2010307020B2 (en) * | 2009-10-12 | 2015-09-24 | Medimmune, Llc | Quantification of IR-A and IR-B for tumor classification |
| WO2011053994A1 (en) | 2009-11-02 | 2011-05-05 | Alnylam Pharmaceuticals, Inc. | Modulation of ldl receptor gene expression with double-stranded rnas targeting the ldl receptor gene promoter |
| WO2011054811A1 (en) | 2009-11-03 | 2011-05-12 | Santaris Pharma A/S | Rna antagonists targeting hsp27 combination therapy |
| WO2011084455A2 (en) | 2009-12-16 | 2011-07-14 | Opko Curna, Llc. | Treatment of membrane bound transcription factor peptidase, site 1 (mbtps1) related diseases by inhibition of natural antisense transcript to mbtps1 |
| EP2515947B1 (en) | 2009-12-23 | 2021-10-06 | CuRNA, Inc. | Treatment of uncoupling protein 2 (ucp2) related diseases by inhibition of natural antisense transcript to ucp2 |
| WO2011079261A2 (en) | 2009-12-23 | 2011-06-30 | Curna, Inc. | Treatment of hepatocyte growth factor (hgf) related diseases by inhibition of natural antisense transcript to hgf |
| KR101838305B1 (ko) | 2009-12-29 | 2018-03-13 | 큐알엔에이, 인크. | ＮＲＦ1(Ｎｕｃｌｅａｒ Ｒｅｓｐｉｒａｔｏｒｙ Ｆａｃｔｏｒ 1)에 대한 천연 안티센스 전사체의 억제에 의한 핵 호흡 인자 1 관련된 질환의 치료 |
| RU2611186C2 (ru) | 2009-12-29 | 2017-02-21 | Курна, Инк. | ЛЕЧЕНИЕ ЗАБОЛЕВАНИЙ, СВЯЗАННЫХ С ОПУХОЛЕВЫМ БЕЛКОМ 63 (р63), ПУТЕМ ИНГИБИРОВАНИЯ ПРИРОДНОГО АНТИСМЫСЛОВОГО ТРАНСКРИПТА К р63 |
| JP6083735B2 (ja) | 2009-12-31 | 2017-02-22 | カッパーアールエヌエー，インコーポレイテッド | インスリン受容体基質２（ｉｒｓ２）および転写因子３（ｔｆｅ３）に対する天然アンチセンス転写物の阻害によるインスリン受容体基質２（ｉｒｓ２）関連疾患の治療 |
| NO2521784T3 (cg-RX-API-DMAC7.html) | 2010-01-04 | 2018-05-05 | ||
| JP5963680B2 (ja) | 2010-01-06 | 2016-08-03 | カッパーアールエヌエー，インコーポレイテッド | 膵臓発生遺伝子に対する天然アンチセンス転写物の阻害による膵臓発生遺伝子疾患の治療 |
| CA2786071C (en) | 2010-01-08 | 2021-01-12 | Isis Pharmaceuticals, Inc. | Modulation of angiopoietin-like 3 expression |
| NO2524039T3 (cg-RX-API-DMAC7.html) | 2010-01-11 | 2018-04-28 | ||
| US20110172296A1 (en) * | 2010-01-12 | 2011-07-14 | Bennett C Frank | Modulation of transforming growth factor-beta 1 expression |
| US8946182B2 (en) | 2010-01-25 | 2015-02-03 | Curna, Inc. | Treatment of RNASE H1 related diseases by inhibition of natural antisense transcript to RNASE H1 |
| US9574191B2 (en) | 2010-02-03 | 2017-02-21 | The Board Of Regents Of The University Of Texas System | Selective inhibition of polyglutamine protein expression |
| EP3628750A1 (en) * | 2010-02-08 | 2020-04-01 | Ionis Pharmaceuticals, Inc. | Selective reduction of allelic variants |
| EP3561060A1 (en) | 2010-02-08 | 2019-10-30 | Ionis Pharmaceuticals, Inc. | Selective reduction of allelic variants |
| CN102844435B (zh) | 2010-02-22 | 2017-05-10 | 库尔纳公司 | 通过抑制吡咯啉‑5‑羧酸还原酶1(pycr1)的天然反义转录物而治疗pycr1相关疾病 |
| WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
| EP2545173A2 (en) * | 2010-03-12 | 2013-01-16 | Sarepta Therapeutics, Inc. | Antisense modulation of nuclear hormone receptors |
| US9340786B2 (en) | 2010-03-24 | 2016-05-17 | Rxi Pharmaceuticals Corporation | RNA interference in dermal and fibrotic indications |
| CA2795145C (en) | 2010-04-02 | 2019-01-22 | Curna, Inc. | Treatment of colony-stimulating factor 3 (csf3) related diseases by inhibition of natural antisense transcript to csf3 |
| US9044494B2 (en) | 2010-04-09 | 2015-06-02 | Curna, Inc. | Treatment of fibroblast growth factor 21 (FGF21) related diseases by inhibition of natural antisense transcript to FGF21 |
| CN102933711B (zh) * | 2010-05-03 | 2018-01-02 | 库尔纳公司 | 通过抑制沉默调节蛋白(sirt)的天然反义转录物而治疗沉默调节蛋白(sirt)相关疾病 |
| TWI531370B (zh) | 2010-05-14 | 2016-05-01 | 可娜公司 | 藉由抑制ｐａｒ４天然反股轉錄本治療ｐａｒ４相關疾病 |
| US8980858B2 (en) | 2010-05-26 | 2015-03-17 | Curna, Inc. | Treatment of methionine sulfoxide reductase a (MSRA) related diseases by inhibition of natural antisense transcript to MSRA |
| CN102947451B (zh) | 2010-05-26 | 2017-09-22 | 库尔纳公司 | 通过抑制无调同源物1(atoh1)的天然反义转录物而治疗atoh1相关疾病 |
| AU2011261213B2 (en) | 2010-06-04 | 2015-05-21 | Board Of Regents, The University Of Texas System | Regulation of metabolism by miR-378 |
| JP5755326B2 (ja) * | 2010-06-11 | 2015-07-29 | 日立化成株式会社 | 腎機能の特徴を決定する方法 |
| WO2011156734A2 (en) | 2010-06-11 | 2011-12-15 | Hitachi Chemical Co., Ltd. | Method of characterizing vascular diseases |
| US9518259B2 (en) | 2010-06-15 | 2016-12-13 | Ionis Pharmaceuticals, Inc. | Compounds and methods for modulating interaction between proteins and target nucleic acids |
| WO2011157827A1 (de) | 2010-06-18 | 2011-12-22 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
| US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
| PT2585596T (pt) | 2010-06-23 | 2021-03-23 | Curna Inc | Tratamento de doenças relacionadas com a subunidade alfa de canais de sódio dependentes de voltagem (scna) por inibição da transcrição antissentido natural para scna |
| TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
| TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
| TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
| KR101886452B1 (ko) | 2010-07-14 | 2018-09-07 | 큐알엔에이, 인크. | 디스크 라지 호모로그(dlg)에 대한 천연 안티센스 전사체의 저해에 의한 dlg 관련된 질환의 치료 |
| WO2012029870A1 (ja) * | 2010-08-31 | 2012-03-08 | 国立大学法人大阪大学 | オリゴヌクレオチド、およびオリゴヌクレオチドを有効成分として含有する脂質異常症治療剤 |
| WO2012034942A1 (en) | 2010-09-13 | 2012-03-22 | Santaris Pharma A/S | Compounds for the modulation of aurora kinase b expression |
| EP2620428B1 (en) | 2010-09-24 | 2019-05-22 | Wave Life Sciences Ltd. | Asymmetric auxiliary group |
| WO2012047956A2 (en) | 2010-10-06 | 2012-04-12 | Opko Curna Llc | Treatment of sialidase 4 (neu4) related diseases by inhibition of natural antisense transcript to neu4 |
| KR101865433B1 (ko) | 2010-10-22 | 2018-07-13 | 큐알엔에이, 인크. | 알파-l 이두로니다아제 (idua)에 대한 자연 안티센스 전사체의 저해에 의한 idua 관련된 질환의 치료 |
| US9920317B2 (en) | 2010-11-12 | 2018-03-20 | The General Hospital Corporation | Polycomb-associated non-coding RNAs |
| CA2817256A1 (en) | 2010-11-12 | 2012-05-18 | The General Hospital Corporation | Polycomb-associated non-coding rnas |
| US10000752B2 (en) | 2010-11-18 | 2018-06-19 | Curna, Inc. | Antagonat compositions and methods of use |
| WO2012066092A1 (en) | 2010-11-19 | 2012-05-24 | Santaris Pharma A/S | Compounds for the modulation of aurora kinase a expression |
| WO2012066093A1 (en) | 2010-11-19 | 2012-05-24 | Santaris Pharma A/S | Compounds for the modulation of pdz-binding kinase (pbk) expression |
| KR102010598B1 (ko) | 2010-11-23 | 2019-08-13 | 큐알엔에이, 인크. | Nanog에 대한 자연 안티센스 전사체의 저해에 의한 nanog 관련된 질환의 치료 |
| US8771696B2 (en) | 2010-11-23 | 2014-07-08 | Regeneron Pharmaceuticals, Inc. | Method of reducing the severity of stress hyperglycemia with human antibodies to the glucagon receptor |
| JO3756B1 (ar) | 2010-11-23 | 2021-01-31 | Regeneron Pharma | اجسام مضادة بشرية لمستقبلات الجلوكاجون |
| WO2012101252A2 (en) | 2011-01-28 | 2012-08-02 | Sanofi | Human antibodies to pcsk9 for use in methods of treating particular groups of subjects |
| PT2670411T (pt) | 2011-02-02 | 2019-06-18 | Excaliard Pharmaceuticals Inc | Compostos anti sentido visando um fator de crescimento do tecido conetivo (ctfg) para utilização num método de tratamento de queloides ou cicatrizes hipertróficas |
| EP3467109A1 (en) * | 2011-02-08 | 2019-04-10 | Ionis Pharmaceuticals, Inc. | Oligomeric compounds comprising bicyclic nucleotides and uses thereof |
| WO2012110457A2 (en) | 2011-02-14 | 2012-08-23 | Santaris Pharma A/S | Compounds for the modulation of osteopontin expression |
| EP2697244B1 (en) * | 2011-04-13 | 2017-05-17 | Ionis Pharmaceuticals, Inc. | Antisense modulation of ptp1b expression |
| WO2012143427A1 (en) | 2011-04-19 | 2012-10-26 | Santaris Pharma A/S | Anti polyomavirus compounds |
| WO2012145729A2 (en) | 2011-04-20 | 2012-10-26 | Smith Holdings, Llc | Methods and compositions for modulating gene expression using components that self assemble in cells and produce rnai activity |
| JP6188686B2 (ja) | 2011-06-09 | 2017-08-30 | カッパーアールエヌエー，インコーポレイテッド | フラタキシン（ｆｘｎ）への天然アンチセンス転写物の阻害によるｆｘｎ関連疾患の治療 |
| EP2717989B1 (en) | 2011-06-10 | 2018-05-30 | Hitachi Chemical Co., Ltd. | Vesicle capturing devices and methods for using same |
| ES2626488T3 (es) | 2011-07-19 | 2017-07-25 | Wave Life Sciences Pte. Ltd. | Procedimientos para la síntesis de ácidos nucleicos funcionalizados |
| AR087305A1 (es) | 2011-07-28 | 2014-03-12 | Regeneron Pharma | Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit |
| EP2742056B2 (en) | 2011-08-11 | 2020-06-10 | Ionis Pharmaceuticals, Inc. | Selective antisense compounds and uses thereof |
| JP6125505B2 (ja) | 2011-09-06 | 2017-05-10 | カッパーアールエヌエー，インコーポレイテッド | 小分子による電位開口型ナトリウムチャネル・アルファサブユニット関連疾患の治療 |
| WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| AU2012308320C1 (en) | 2011-09-14 | 2018-08-23 | Translate Bio Ma, Inc. | Multimeric oligonucleotide compounds |
| EP2756004B1 (en) | 2011-09-16 | 2019-12-25 | Regeneron Pharmaceuticals, Inc. | INHIBITOR OF PROPROTEIN CONVERTASE SUBTILISIN KEXIN-9 (PCSK9) FOR USE IN REDUCING LIPOPROTEIN(a) LEVELS |
| RU2598709C2 (ru) * | 2011-09-20 | 2016-09-27 | Айсис Фармасьютикалс, Инк. | Антисмысловая регуляция экспрессии gcgr |
| WO2013045413A1 (en) | 2011-09-27 | 2013-04-04 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| WO2013063313A1 (en) | 2011-10-25 | 2013-05-02 | Isis Pharmaceuticals, Inc. | Antisense modulation of gccr expression |
| CA3106312C (en) | 2011-12-16 | 2025-09-23 | National University Corporation Tokyo Medical And Dental University | CHIMERIC DOUBLE-STRANDED NUCLEIC ACID |
| TR201815503T4 (tr) | 2012-03-15 | 2018-11-21 | Curna Inc | Beyin kaynaklı nörotrofik faktör (bknf) ile ilişkili hastalıkların doğal antisens transkriptinin bknf'ye inhibisyonu ile muamelesi. |
| EP2831231A1 (en) | 2012-03-30 | 2015-02-04 | Isis Pharmaceuticals, Inc. | Compositions and methods for modulating tau expression for reducing seizure and modifying a neurodegenerative syndrome |
| EP3336189A1 (en) | 2012-04-20 | 2018-06-20 | Ionis Pharmaceuticals, Inc. | Oligomeric compounds comprising bicyclic nucleotides and uses thereof |
| US9255154B2 (en) | 2012-05-08 | 2016-02-09 | Alderbio Holdings, Llc | Anti-PCSK9 antibodies and use thereof |
| AU2013262700A1 (en) | 2012-05-16 | 2015-01-22 | Rana Therapeutics, Inc. | Compositions and methods for modulating hemoglobin gene family expression |
| EP2850185A4 (en) | 2012-05-16 | 2015-12-30 | Rana Therapeutics Inc | COMPOSITIONS AND METHOD FOR MODULATING UTRN GENE EXPRESSION |
| EP3511416A1 (en) * | 2012-05-16 | 2019-07-17 | Translate Bio MA, Inc. | Compositions and methods for modulating gene expression |
| US20150152410A1 (en) | 2012-05-16 | 2015-06-04 | Rana Therapeutics, Inc. | Compositions and methods for modulating mecp2 expression |
| BR112014028646A2 (pt) * | 2012-05-16 | 2017-08-15 | Rana Therapeutics Inc | Composições e métodos para modulação da expressão de pten |
| CA2873794A1 (en) | 2012-05-16 | 2013-11-21 | Rana Therapeutics Inc. | Compositions and methods for modulating smn gene family expression |
| WO2013173598A1 (en) | 2012-05-16 | 2013-11-21 | Rana Therapeutics, Inc. | Compositions and methods for modulating atp2a2 expression |
| US10837014B2 (en) | 2012-05-16 | 2020-11-17 | Translate Bio Ma, Inc. | Compositions and methods for modulating SMN gene family expression |
| WO2013173789A2 (en) | 2012-05-17 | 2013-11-21 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide compositions |
| RU2624028C2 (ru) * | 2012-05-24 | 2017-06-30 | Ионис Фармасьютикалз, Инк. | Способы и композиции для модулирования экспрессии аполипопротеина (а) |
| EP2857513A4 (en) * | 2012-05-26 | 2016-05-25 | Bonac Corp | Single-stranded nucleic acid molecule controlling the expression of a gene transporter |
| BR112015000723A2 (pt) | 2012-07-13 | 2017-06-27 | Shin Nippon Biomedical Laboratories Ltd | adjuvante de ácido nucléico quiral |
| ES2862073T3 (es) | 2012-07-13 | 2021-10-06 | Wave Life Sciences Ltd | Grupo auxiliar asimétrico |
| ES2940887T3 (es) | 2012-07-13 | 2023-05-12 | Wave Life Sciences Ltd | Método de preparación de oligonucleótidos quirales |
| US20150247141A1 (en) | 2012-09-14 | 2015-09-03 | Rana Therapeutics, Inc. | Multimeric oligonucleotide compounds |
| US9993522B2 (en) | 2012-09-18 | 2018-06-12 | Uti Limited Partnership | Treatment of pain by inhibition of USP5 de-ubiquitinase |
| WO2014059353A2 (en) * | 2012-10-11 | 2014-04-17 | Isis Pharmaceuticals, Inc. | Oligomeric compounds comprising bicyclic nucleosides and uses thereof |
| EP2906255B1 (en) | 2012-10-12 | 2023-02-22 | Ionis Pharmaceuticals, Inc. | Antisense compounds and uses thereof |
| AU2013331434B2 (en) | 2012-10-15 | 2019-08-08 | Ionis Pharmaceuticals, Inc. | Compositions for modulating C90RF72 expression |
| EP2906697A4 (en) | 2012-10-15 | 2016-06-22 | Ionis Pharmaceuticals Inc | METHOD FOR MONITORING THE C9ORF72 EXPRESSION |
| WO2014076196A1 (en) * | 2012-11-15 | 2014-05-22 | Santaris Pharma A/S | Anti apob antisense conjugate compounds |
| JP6463687B2 (ja) | 2012-11-26 | 2019-02-06 | ロシュ・イノベーション・センター・コペンハーゲン・アクティーゼルスカブＲｏｃｈｅ Ｉｎｎｏｖａｔｉｏｎ Ｃｅｎｔｅｒ Ｃｏｐｅｎｈａｇｅｎ Ａ／Ｓ | Ｆｇｆｒ３の発現の調節のための組成物及び方法 |
| JP6580993B2 (ja) | 2013-01-30 | 2019-09-25 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | Ｌｎａオリゴヌクレオチド糖質コンジュゲート |
| DK2951191T3 (en) * | 2013-01-31 | 2019-01-14 | Ionis Pharmaceuticals Inc | PROCEDURE FOR MANUFACTURING OLIGOMERIC COMPOUNDS USING MODIFIED CLUTCH PROTOCOLS |
| US10398661B2 (en) | 2013-02-28 | 2019-09-03 | The Board Of Regents Of The University Of Texas System | Methods for classifying a cancer as susceptible to TMEPAI-directed therapies and treating such cancers |
| CA2901983A1 (en) | 2013-03-01 | 2014-09-04 | National University Corporation Tokyo Medical And Dental University | Chimeric single-stranded antisense polynucleotides and double-stranded antisense agent |
| EP2970970B1 (en) | 2013-03-14 | 2018-12-12 | Andes Biotechnologies Global, Inc. | Antisense oligonucleotides for treatment of cancer stem cells |
| EP2971142B1 (en) | 2013-03-14 | 2020-06-24 | Ionis Pharmaceuticals, Inc. | Compositions and methods for modulating tau expression |
| WO2014145356A1 (en) * | 2013-03-15 | 2014-09-18 | MiRagen Therapeutics, Inc. | Bridged bicyclic nucleosides |
| AU2014255381A1 (en) | 2013-04-17 | 2015-10-08 | Pfizer Inc. | N-piperidin-3-ylbenzamide derivatives for treating cardiovascular diseases |
| HUE050394T2 (hu) * | 2013-05-01 | 2020-11-30 | Ionis Pharmaceuticals Inc | Apolipoprotein(a) expressziójának módosítására szolgáló eljárások és készítmények |
| US9662649B2 (en) | 2013-05-06 | 2017-05-30 | Hitachi Chemical Company America, Ltd. | Devices and methods for capturing target molecules |
| HK1213595A1 (zh) | 2013-05-24 | 2016-07-08 | 罗氏创新中心哥本哈根有限公司 | B-细胞cll/淋巴瘤11a(bcl11a)的寡核苷酸调节剂及其用途 |
| CN105264073A (zh) | 2013-05-30 | 2016-01-20 | 国立大学法人东京医科齿科大学 | 用于递送治疗性寡核苷酸的双链剂 |
| US10111953B2 (en) | 2013-05-30 | 2018-10-30 | Regeneron Pharmaceuticals, Inc. | Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9) |
| EA201592267A1 (ru) | 2013-06-07 | 2016-04-29 | Ридженерон Фармасьютикалз, Инк. | Способы ингибирования атеросклероза посредством введения ингибитора pcsk9 |
| US10190117B2 (en) | 2013-06-16 | 2019-01-29 | National University Corporation Tokyo Medical And Dental University | Double-stranded antisense nucleic acid with exon-skipping effect |
| HRP20200163T1 (hr) | 2013-06-27 | 2020-08-07 | Roche Innovation Center Copenhagen A/S | Antisens oligomeri i konjugati koji ciljno djeluju na pcsk9 |
| TWI657819B (zh) | 2013-07-19 | 2019-05-01 | 美商Ionis製藥公司 | 用於調節τ蛋白表現之組合物 |
| JP2016531570A (ja) | 2013-08-16 | 2016-10-13 | ラナ セラピューティクス インコーポレイテッド | ユークロマチン領域を標的とするオリゴヌクレオチド |
| MX2016004651A (es) * | 2013-10-11 | 2016-08-05 | Ionis Pharmaceuticals Inc | Composiciones para modular la expresion de c9orf72. |
| EA201690889A1 (ru) | 2013-11-12 | 2016-11-30 | Санофи Байотекнолоджи | Режимы дозирования для применения ингибиторов pcsk9 |
| US20170037409A1 (en) | 2013-12-24 | 2017-02-09 | Ionis Pharmaceuticals, Inc. | Modulation of angiopoietin-like 3 expression |
| EP3088524A4 (en) | 2013-12-26 | 2017-08-09 | Tokyo Medical University | Artificial mimic mirna for controlling gene expression, and use of same |
| BR112016014986A2 (pt) | 2013-12-27 | 2018-01-23 | Bonac Corporation | mirna tipo correspondência artificial, composição e método para suprimir expressão de um gene alvo, composição farmacêutica, método para tratar uma doença, e, ácido nucleico de fita única |
| US10322173B2 (en) | 2014-01-15 | 2019-06-18 | Shin Nippon Biomedical Laboratories, Ltd. | Chiral nucleic acid adjuvant having anti-allergic activity, and anti-allergic agent |
| WO2015108047A1 (ja) | 2014-01-15 | 2015-07-23 | 株式会社新日本科学 | 免疫誘導活性を有するキラル核酸アジュバンド及び免疫誘導活性剤 |
| JPWO2015108048A1 (ja) | 2014-01-15 | 2017-03-23 | 株式会社新日本科学 | 抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤 |
| CN113278617A (zh) | 2014-01-16 | 2021-08-20 | 波涛生命科学有限公司 | 手性设计 |
| KR20200102553A (ko) | 2014-05-01 | 2020-08-31 | 아이오니스 파마수티컬즈, 인코포레이티드 | 성장 호르몬 수용체 발현을 조절하기 위한 조성물 및 방법 |
| AU2015252895B2 (en) | 2014-05-01 | 2021-07-15 | Ionis Pharmaceuticals, Inc. | Compositions and methods for modulating angiopoietin-like 3 expression |
| CN106232804B (zh) | 2014-05-01 | 2019-10-25 | Ionis制药公司 | 用于调节补体因子b表达的组合物和方法 |
| GB201408623D0 (en) | 2014-05-15 | 2014-07-02 | Santaris Pharma As | Oligomers and oligomer conjugates |
| WO2015179693A1 (en) | 2014-05-22 | 2015-11-26 | Isis Pharmaceuticals, Inc. | Conjugated antisense compounds and their use |
| GB201410693D0 (en) | 2014-06-16 | 2014-07-30 | Univ Southampton | Splicing modulation |
| PL3169353T3 (pl) | 2014-07-16 | 2020-06-01 | Sanofi Biotechnology | SPOSOBY LECZENIA PACJENTÓW Z HETEROZYGOTYCZNĄ HIPERCHOLESTEROLEMIĄ RODZINNĄ (heFH) |
| TWI703214B (zh) * | 2014-07-31 | 2020-09-01 | 中央研究院 | 具拮抗ｐｄ-１功能的適體分子於癌症治療相關之應用 |
| WO2016024205A1 (en) | 2014-08-15 | 2016-02-18 | Pfizer Inc. | Oligomers targeting hexanucleotide repeat expansion in human c9orf72 gene |
| CA2958524A1 (en) * | 2014-08-20 | 2016-02-25 | Lifesplice Pharma Llc | Splice modulating oligonucleotides and methods of use thereof |
| WO2016040589A1 (en) | 2014-09-12 | 2016-03-17 | Alnylam Pharmaceuticals, Inc. | Polynucleotide agents targeting complement component c5 and methods of use thereof |
| CA2960763A1 (en) | 2014-09-16 | 2016-03-24 | Regeneron Pharmaceuticals, Inc. | Anti-glucagon antibodies and uses thereof |
| CN107109411B (zh) | 2014-10-03 | 2022-07-01 | 冷泉港实验室 | 核基因输出的定向增加 |
| US20170327524A1 (en) | 2014-10-10 | 2017-11-16 | Hoffmann-La Roche, Inc. | Galnac phosphoramidites, nucleic acid conjugates thereof and their use |
| EP3207138B1 (en) | 2014-10-17 | 2020-07-15 | Alnylam Pharmaceuticals, Inc. | Polynucleotide agents targeting aminolevulinic acid synthase-1 (alas1) and uses thereof |
| WO2016069694A2 (en) | 2014-10-30 | 2016-05-06 | Alnylam Pharmaceuticals, Inc. | Polynucleotide agents targeting serpinc1 (at3) and methods of use thereof |
| WO2016070060A1 (en) | 2014-10-30 | 2016-05-06 | The General Hospital Corporation | Methods for modulating atrx-dependent gene repression |
| US10266895B2 (en) | 2014-11-05 | 2019-04-23 | Hitachi Chemical Company Ltd. | Exosomes and microvesicles in intestinal luminal fluids and stool and use of same for the assessment of inflammatory bowel disease |
| JP6631852B2 (ja) | 2014-11-12 | 2020-01-15 | 日立化成株式会社 | 臓器障害を診断するための方法および装置 |
| CA3193811A1 (en) | 2014-11-14 | 2016-05-19 | Voyager Therapeutics, Inc. | Compositions and methods of treating amyotrophic lateral sclerosis (als) |
| WO2016096938A1 (en) | 2014-12-16 | 2016-06-23 | Roche Innovation Center Copenhagen A/S | Chiral toxicity screening method |
| EP3239297B1 (en) | 2014-12-27 | 2021-03-10 | Bonac Corporation | Naturally occuring mirna for controlling gene expression, and use of same |
| CN107922946A (zh) | 2015-02-04 | 2018-04-17 | 霍夫曼-拉罗奇有限公司 | Tau反义低聚物及其用途 |
| CN107636159B (zh) | 2015-02-04 | 2022-06-14 | 百时美施贵宝公司 | 选择治疗性分子的方法 |
| WO2016130943A1 (en) | 2015-02-13 | 2016-08-18 | Rana Therapeutics, Inc. | Hybrid oligonucleotides and uses thereof |
| EP3271460A4 (en) | 2015-03-17 | 2019-03-13 | The General Hospital Corporation | RNA INTERACTOM OF POLYCOMB REPRESSIVE COMPLEX 1 (PRC1) |
| US10376535B2 (en) | 2015-03-26 | 2019-08-13 | University Of Rochester | Therapy for malignant disease |
| JP6602847B2 (ja) | 2015-03-27 | 2019-11-06 | 株式会社ボナック | デリバリー機能と遺伝子発現制御能を有する一本鎖核酸分子 |
| MX2017012610A (es) | 2015-04-08 | 2018-03-16 | Alnylam Pharmaceuticals Inc | Composiciones y metodos para inhibir la expresion del gen lect2. |
| SG11201708468YA (en) | 2015-04-16 | 2017-11-29 | Ionis Pharmaceuticals Inc | Compositions for modulating c9orf72 expression |
| EP3310918B1 (en) | 2015-06-18 | 2020-08-05 | Alnylam Pharmaceuticals, Inc. | Polynucleotide agents targeting hydroxyacid oxidase (glycolate oxidase, hao1) and methods of use thereof |
| US20180188257A1 (en) | 2015-06-19 | 2018-07-05 | University Of Rochester | Septin proteins as novel biomarkers for detection and treatment of müllerian cancers |
| AU2016294347B2 (en) * | 2015-07-10 | 2022-07-28 | Ionis Pharmaceuticals, Inc. | Modulators of diacyglycerol acyltransferase 2 (DGAT2) |
| MA43072A (fr) | 2015-07-22 | 2018-05-30 | Wave Life Sciences Ltd | Compositions d'oligonucléotides et procédés associés |
| AU2016308111A1 (en) | 2015-08-18 | 2018-03-01 | Regeneron Pharmaceuticals, Inc. | Anti-PCSK9 inhibitory antibodies for treating patients with hyperlipidemia undergoing lipoprotein apheresis |
| DE112016003948T5 (de) | 2015-08-31 | 2018-05-09 | City Of Sapporo | Molekulare verfahren zum beurteilen einer urothelialen erkrankung |
| CN108135845B (zh) | 2015-09-18 | 2021-10-29 | Dnarx公司 | 用于体内核酸表达的系统和方法 |
| KR102422625B1 (ko) | 2015-10-09 | 2022-07-20 | 유니버시티 오브 사우스앰톤 | 유전자 발현의 조절 및 탈조절된 단백질 발현의 스크리닝 |
| EP3365446A4 (en) | 2015-10-19 | 2019-06-26 | Phio Pharmaceuticals Corp. | SMALL SELF-LEANING NUCLEIC ACID COMPOUNDS TURNED AGAINST LONG NON-CODING RNA |
| EP3394258B1 (en) | 2015-10-22 | 2021-09-22 | Roche Innovation Center Copenhagen A/S | In vitro toxicity screening assay |
| WO2017079291A1 (en) | 2015-11-02 | 2017-05-11 | Ionis Pharmaceuticals, Inc. | Compounds and methods for modulating c90rf72 |
| EP3370708A4 (en) | 2015-11-06 | 2019-06-26 | Ionis Pharmaceuticals, Inc. | MODULATION OF APOLIPOPROTEIN (A) EXPRESSION |
| SG11201803951QA (en) | 2015-11-12 | 2018-06-28 | Hoffmann La Roche | Oligonucleotides for inducing paternal ube3a expression |
| KR102604132B1 (ko) | 2015-12-14 | 2023-11-17 | 콜드스프링하버러보러토리 | 상염색체 우성 정신 지체 5 및 드라베 증후군의 치료를 위한 안티센스 올리고머 |
| US11096956B2 (en) | 2015-12-14 | 2021-08-24 | Stoke Therapeutics, Inc. | Antisense oligomers and uses thereof |
| EP3418289A4 (en) | 2016-02-17 | 2019-10-30 | Tokyo Institute of Technology | ARTIFICIAL NUCLEOSIDE AND ARTIFICIAL NUCLEOTIDE AND ARTIFICIAL OLIGONUCLEOTIDE |
| WO2017152182A1 (en) | 2016-03-04 | 2017-09-08 | Rhode Island Hospital | Targeting microrna for cancer treatment |
| MX2018010830A (es) | 2016-03-14 | 2019-02-07 | Hoffmann La Roche | Oligonucleotidos para reducir la expresion de pd-l1. |
| JP6985288B2 (ja) | 2016-04-14 | 2021-12-22 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | トリチル−モノ−ＧａｌＮＡｃ化合物とその利用 |
| US11390867B2 (en) | 2016-04-29 | 2022-07-19 | Nanyang Technological University | G-quadruplex-containing antisense oligonucleotides |
| JP7097820B2 (ja) * | 2016-05-12 | 2022-07-08 | ロシュ イノベーション センター コペンハーゲン エーエス | ヌクレオシドまたはオリゴヌクレオチドへの、立体的に規定されたオキサザホスホリジンホスホルアミダイト単量体のカップリングの増大法 |
| MA45496A (fr) | 2016-06-17 | 2019-04-24 | Hoffmann La Roche | Molécules d'acide nucléique pour la réduction de l'arnm de padd5 ou pad7 pour le traitement d'une infection par l'hépatite b |
| US11105794B2 (en) | 2016-06-17 | 2021-08-31 | Hoffmann-La Roche Inc. | In vitro nephrotoxicity screening assay |
| JP7012033B2 (ja) | 2016-06-17 | 2022-02-10 | エフ．ホフマン－ラ ロシュ アーゲー | インビトロ腎毒性スクリーニングアッセイ |
| JP7129702B2 (ja) | 2016-09-29 | 2022-09-02 | 国立大学法人 東京医科歯科大学 | オーバーハングを有する二本鎖核酸複合体 |
| JOP20190065A1 (ar) | 2016-09-29 | 2019-03-28 | Ionis Pharmaceuticals Inc | مركبات وطرق لتقليل التعبير عن tau |
| WO2018067900A1 (en) | 2016-10-06 | 2018-04-12 | Ionis Pharmaceuticals, Inc. | Method of conjugating oligomeric compounds |
| WO2018075792A1 (en) | 2016-10-20 | 2018-04-26 | Regeneron Pharmaceuticals, Inc. | Methods of lowering blood glucose levels |
| WO2018085656A1 (en) * | 2016-11-03 | 2018-05-11 | Ohio State Innovation Foundation | Antisense oligomers targeting hoxb-as3 long non-coding rna |
| EP3548005A4 (en) | 2016-11-29 | 2020-06-17 | Puretech Health LLC | Exosomes for delivery of therapeutic agents |
| WO2018130581A1 (en) | 2017-01-13 | 2018-07-19 | Roche Innovation Center Copenhagen A/S | Antisense oligonucleotides for modulating rela expression |
| EP3568481A1 (en) | 2017-01-13 | 2019-11-20 | Roche Innovation Center Copenhagen A/S | Antisense oligonucleotides for modulating relb expression |
| US20190345495A1 (en) | 2017-01-13 | 2019-11-14 | Roche Innovation Center Copenhagen A/S | Antisense oligonucleotides for modulating nfkb2 expression |
| EP3568479A1 (en) | 2017-01-13 | 2019-11-20 | Roche Innovation Center Copenhagen A/S | Antisense oligonucleotides for modulating nfkb1 expression |
| US20190338286A1 (en) | 2017-01-13 | 2019-11-07 | Roche Innovation Center Copenhagen A/S | Antisense oligonucleotides for modulating rel expression |
| MX2019009305A (es) | 2017-02-06 | 2019-09-19 | Nissan Chemical Corp | Oligonucleotido de cadena simple. |
| WO2018155450A1 (ja) * | 2017-02-21 | 2018-08-30 | 国立大学法人大阪大学 | アンチセンスオリゴ核酸 |
| WO2018165564A1 (en) | 2017-03-09 | 2018-09-13 | Ionis Pharmaceuticals, Inc. | Morpholino modified oligomeric compounds |
| US11541130B2 (en) | 2017-03-23 | 2023-01-03 | DNARx | Systems and methods for nucleic acid expression in vivo |
| JOP20190215A1 (ar) * | 2017-03-24 | 2019-09-19 | Ionis Pharmaceuticals Inc | مُعدّلات التعبير الوراثي عن pcsk9 |
| US11638717B2 (en) | 2017-03-29 | 2023-05-02 | Shionogi & Co., Ltd. | Complex of nucleic acid medicine and multibranched lipid |
| NO344051B1 (en) * | 2017-05-04 | 2019-08-26 | Patogen As | Novel virus in Fish and Method for detection |
| EP3618839A4 (en) | 2017-05-05 | 2021-06-09 | Voyager Therapeutics, Inc. | Compositions and methods of treating amyotrophic lateral sclerosis (als) |
| JP6952366B2 (ja) * | 2017-05-26 | 2021-10-20 | 国立研究開発法人国立循環器病研究センター | Ｐｃｓｋ９を標的としたアンチセンス核酸 |
| JP6974872B2 (ja) | 2017-06-30 | 2021-12-01 | 国立大学法人 東京医科歯科大学 | ヘテロ二本鎖型ａｎｔｉｍｉＲ |
| US11555188B2 (en) | 2017-07-26 | 2023-01-17 | Nissan Chemical Corporation | Single-stranded oligonucleotide |
| CN111278991B (zh) | 2017-08-25 | 2022-04-01 | 斯托克制药公司 | 用于治疗病况和疾病的反义寡聚体 |
| WO2019079242A1 (en) | 2017-10-16 | 2019-04-25 | Voyager Therapeutics, Inc. | TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS) |
| RU2766360C2 (ru) | 2017-10-16 | 2022-03-15 | Ф. Хоффманн-Ля Рош Аг | МОЛЕКУЛЫ НУКЛЕИНОВЫХ КИСЛОТ ДЛЯ УМЕНЬШЕНИЯ УРОВНЯ мРНК PAPD5 ИЛИ PAPD7 ДЛЯ ЛЕЧЕНИЯ ИНФЕКЦИОННОГО ГЕПАТИТА В |
| AU2018352236B2 (en) | 2017-10-16 | 2025-04-10 | The Curators Of The University Of Missouri | Treatment of amyotrophic lateral sclerosis (ALS) |
| CN111344408A (zh) | 2017-12-11 | 2020-06-26 | 哥本哈根罗氏创新中心 | 用于调控fndc3b表达的寡核苷酸 |
| US20200378970A1 (en) | 2017-12-21 | 2020-12-03 | Hoffmann-La Roche Inc. | Companion diagnostic for htra1 rna antagonists |
| KR20200104345A (ko) | 2017-12-22 | 2020-09-03 | 로슈 이노베이션 센터 코펜하겐 에이/에스 | 포스포로디티오에이트 뉴클레오시드간 연결을 포함하는 올리고뉴클레오티드 |
| JP2021508327A (ja) | 2017-12-22 | 2021-03-04 | ロシュ イノベーション センター コペンハーゲン エーエス | 新規のチオホスホラミダイト |
| EP3728591B1 (en) | 2017-12-22 | 2025-07-23 | Roche Innovation Center Copenhagen A/S | Gapmer oligonucleotides comprising a phosphorodithioate internucleoside linkage |
| US20210095274A1 (en) | 2018-01-10 | 2021-04-01 | Roche Innovation Center Copenhagen A/S | Oligonucleotides for modulating pias4 expression |
| JP2021510295A (ja) | 2018-01-12 | 2021-04-22 | ロシュ イノベーション センター コペンハーゲン エーエス | Ｇｓｋ３ｂ発現を調節するためのオリゴヌクレオチド |
| KR20200109338A (ko) | 2018-01-12 | 2020-09-22 | 로슈 이노베이션 센터 코펜하겐 에이/에스 | 알파-시누클레인 안티센스 올리고뉴클레오티드 및 이의 용도 |
| US11447775B2 (en) | 2018-01-12 | 2022-09-20 | Bristol-Myers Squibb Company | Antisense oligonucleotides targeting alpha-synuclein and uses thereof |
| MX2020007439A (es) | 2018-01-12 | 2020-09-14 | Bristol Myers Squibb Co | Oligonucleotidos antisentido que actuan sobre alfa-sinucleina y usos de estos. |
| JP2021510525A (ja) | 2018-01-17 | 2021-04-30 | ロシュ イノベーション センター コペンハーゲン エーエス | Ｅｒｃ１発現を調節するためのオリゴヌクレオチド |
| WO2019145386A1 (en) | 2018-01-26 | 2019-08-01 | Roche Innovation Center Copenhagen A/S | Oligonucleotides for modulating csnk1d expression |
| CN112020559A (zh) | 2018-02-21 | 2020-12-01 | 百时美施贵宝公司 | Camk2d反义寡核苷酸及其用途 |
| EP3760209B1 (en) | 2018-02-28 | 2023-11-22 | National University Corporation Tokyo Medical and Dental University | Ischemic-lesion-site-specific gene therapy |
| JP7394392B2 (ja) | 2018-03-14 | 2023-12-08 | 国立大学法人 東京医科歯科大学 | 核酸複合体 |
| WO2019181946A1 (ja) | 2018-03-19 | 2019-09-26 | 国立大学法人東京医科歯科大学 | 毒性が軽減した核酸 |
| CA3094303A1 (en) | 2018-03-20 | 2019-09-26 | Tokyo Institute Of Technology | Antisense oligonucleotide reduced in toxicity |
| JP7262816B2 (ja) | 2018-03-22 | 2023-04-24 | 国立大学法人 東京医科歯科大学 | ヘテロ核酸のｂｂｂ通過脂質リガンド |
| CA3095134A1 (en) | 2018-03-28 | 2019-10-03 | Board Of Regents, The University Of Texas System | Identification of epigenetic alterations in dna isolated from exosomes |
| BR112020020220A8 (pt) | 2018-04-05 | 2021-02-17 | Centre Leon Berard | uso de inibidores da fubp1 para o tratamento de infecção pelo vírus da hepatite b |
| US12060558B2 (en) | 2018-05-04 | 2024-08-13 | Stoke Therapeutics, Inc. | Methods and compositions for treatment of cholesteryl ester storage disease |
| CR20200605A (es) | 2018-05-09 | 2021-01-29 | Ionis Pharmaceuticals Inc | Compuestos y métodos para la reducción de la expresión de fxi |
| AU2019287635A1 (en) * | 2018-06-14 | 2020-12-17 | Ionis Pharmaceuticals, Inc. | Compounds and methods for increasing STMN2 expression |
| CN112567035A (zh) | 2018-07-02 | 2021-03-26 | 沃雅戈治疗公司 | 肌萎缩侧索硬化症及脊髓相关病症的治疗 |
| CA3103054A1 (en) | 2018-07-03 | 2020-01-09 | F. Hoffmann-La Roche Ag | Oligonucleotides for modulating tau expression |
| JP7616987B2 (ja) | 2018-07-13 | 2025-01-17 | エフ． ホフマン－ラ ロシュ アーゲー | Ｒｔｅｌ１発現の調節用のオリゴヌクレオチド |
| CN112512584A (zh) | 2018-07-27 | 2021-03-16 | 国立大学法人大阪大学 | 用于抑制衰老、预防、改善或治疗衰老相关疾病或症状、或者延长寿命的组合物 |
| EP4122943B1 (en) | 2018-07-31 | 2024-05-29 | Roche Innovation Center Copenhagen A/S | Oligonucleotides comprising a phosphorotrithioate internucleoside linkage |
| CN119912512A (zh) | 2018-07-31 | 2025-05-02 | 罗氏创新中心哥本哈根有限公司 | 包含三硫代磷酸酯核苷间键的寡核苷酸 |
| US12018087B2 (en) | 2018-08-02 | 2024-06-25 | Dyne Therapeutics, Inc. | Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject |
| EA202190416A1 (ru) | 2018-08-02 | 2021-06-23 | Дайн Терапьютикс, Инк. | Мышечно-специфические комлексы и их применение для лечения плече-лопаточно-лицевой мышечной дистрофии |
| US12370264B1 (en) | 2018-08-02 | 2025-07-29 | Dyne Therapeutics, Inc. | Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subject |
| US12097263B2 (en) | 2018-08-02 | 2024-09-24 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| US11911484B2 (en) | 2018-08-02 | 2024-02-27 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| WO2020077390A1 (en) * | 2018-10-18 | 2020-04-23 | Murdoch University | Antisense therapy for ptp1b related conditions |
| TW202102516A (zh) | 2019-02-20 | 2021-01-16 | 丹麥商羅氏創新中心哥本哈根有限公司 | 膦醯基乙酸酯間隙子寡核苷酸 |
| CN113474352A (zh) | 2019-02-20 | 2021-10-01 | 罗氏创新中心哥本哈根有限公司 | 新型亚磷酰胺 |
| WO2020184700A1 (ja) | 2019-03-14 | 2020-09-17 | レナセラピューティクス株式会社 | Ｉｈｈ発現を調節するための核酸複合体 |
| JP7687682B2 (ja) | 2019-04-08 | 2025-06-03 | 国立大学法人東京科学大学 | 筋疾患治療用医薬組成物 |
| EP4005602A4 (en) | 2019-07-30 | 2024-06-12 | Shionogi & Co., Ltd | NUCLEIC ACID AGENT TARGETED AGAINST MURF1 |
| EP4013872A1 (en) | 2019-08-14 | 2022-06-22 | Codiak BioSciences, Inc. | Extracellular vesicles with antisense oligonucleotides targeting kras |
| CN114729366A (zh) | 2019-08-14 | 2022-07-08 | 科迪亚克生物科学公司 | 靶向CEBP/β的细胞外囊泡-ASO构建体 |
| WO2021030773A1 (en) | 2019-08-14 | 2021-02-18 | Codiak Biosciences, Inc. | Extracellular vesicle-nlrp3 antagonist |
| MX2022001767A (es) | 2019-08-14 | 2022-06-09 | Codiak Biosciences Inc | Construcciones de vesículas-oligonucleótidos antisentido (aso) extracelulares que se dirigen a transductor de señal y activador de la transcripción 6 (stat6). |
| CN114729327A (zh) | 2019-08-14 | 2022-07-08 | 科迪亚克生物科学公司 | 具有stat3反义寡核苷酸的细胞外囊泡 |
| CN114555621B (zh) | 2019-08-15 | 2025-10-28 | Ionis制药公司 | 键修饰的寡聚化合物及其用途 |
| EP4019088A4 (en) * | 2019-08-23 | 2024-01-17 | National University Corporation Tokai National Higher Education and Research System | INHIBITOR OF RNA ACTION AND ITS USE |
| WO2021054370A1 (ja) | 2019-09-18 | 2021-03-25 | 国立大学法人東京医科歯科大学 | 核酸複合体 |
| WO2021062058A1 (en) | 2019-09-25 | 2021-04-01 | Codiak Biosciences, Inc. | Sting agonist comprising exosomes for treating neuroimmunological disorders |
| CN115103911A (zh) | 2019-10-11 | 2022-09-23 | 国立大学法人东京医科齿科大学 | 修饰的异源核酸 |
| CA3163646A1 (en) | 2019-12-24 | 2021-07-01 | F. Hoffman-La Roche Ag | Pharmaceutical combination of antiviral agents targeting hbv and/or an immune modulator for treatment of hbv |
| JP2023509870A (ja) | 2019-12-24 | 2023-03-10 | エフ． ホフマン－ラ ロシュ アーゲー | Ｈｂｖの処置のためのｈｂｖを標的とする治療用オリゴヌクレオチドとｔｌｒ７アゴニストとの医薬組合せ |
| EP4098747A4 (en) | 2020-01-31 | 2025-03-26 | Sanwa Kagaku Kenkyusho Co., Ltd. | ATN1 ANTISENSE OLIGONUCLEOTIDE |
| JPWO2021177418A1 (cg-RX-API-DMAC7.html) | 2020-03-04 | 2021-09-10 | ||
| WO2021184021A1 (en) | 2020-03-13 | 2021-09-16 | Codiak Biosciences, Inc. | Extracellular vesicle-aso constructs targeting pmp22 |
| WO2021184020A1 (en) | 2020-03-13 | 2021-09-16 | Codiak Biosciences, Inc. | Methods of treating neuroinflammation |
| EP4123023A4 (en) | 2020-03-16 | 2024-07-17 | National University Corporation Tokyo Medical and Dental University | Heteronucleic acid containing morpholino nucleic acid |
| EP4121534A1 (en) | 2020-03-18 | 2023-01-25 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for treating subjects having a heterozygous alanine-glyoxylate aminotransferase gene (agxt) variant |
| CN115867657A (zh) | 2020-05-11 | 2023-03-28 | 斯托克制药公司 | 用于治疗疾患和疾病的opa1反义寡聚物 |
| JP7751302B2 (ja) | 2020-06-15 | 2025-10-08 | リードファーマ株式会社 | 架橋型ヌクレオシドおよびヌクレオチド |
| WO2022076596A1 (en) | 2020-10-06 | 2022-04-14 | Codiak Biosciences, Inc. | Extracellular vesicle-aso constructs targeting stat6 |
| WO2022081725A1 (en) * | 2020-10-16 | 2022-04-21 | The Scripps Research Institute | Therapeutic uses of glucocorticoids with anabolic effects in skeletal muscle |
| US11987795B2 (en) | 2020-11-24 | 2024-05-21 | The Broad Institute, Inc. | Methods of modulating SLC7A11 pre-mRNA transcripts for diseases and conditions associated with expression of SLC7A11 |
| CR20230308A (es) | 2020-12-11 | 2023-09-08 | Civi Biopharma Inc | Entrega oral de conjugados antisentido que tienen por blanco a pcsk9 |
| US20250304966A1 (en) | 2020-12-23 | 2025-10-02 | Argonaute RNA Limited | Treatment of cardiovascular disease |
| JP2024503609A (ja) | 2020-12-31 | 2024-01-26 | ダイン セラピューティクス，インコーポレーテッド | 筋緊張性ジストロフィーを処置するための筋標的化複合体およびその使用 |
| CN117157093A (zh) | 2021-02-17 | 2023-12-01 | 隆萨销售股份有限公司 | 细胞外囊泡-nlrp3拮抗剂 |
| IL305873A (en) | 2021-04-01 | 2023-11-01 | Lonza Sales Ag | Extracellular vesicle compositions |
| US20240240183A1 (en) | 2021-05-25 | 2024-07-18 | National University Corporation Tokyo Medical And Dental University | Heteronucleic acid containing scpBNA or AmNA |
| EP4347829A1 (en) | 2021-05-29 | 2024-04-10 | 1Globe Health Institute LLC | Asymmetric short duplex dna as a novel gene silencing technology and use thereof |
| AU2022286925A1 (en) | 2021-05-29 | 2023-12-21 | 1Globe Health Institute Llc | Short duplex dna as a novel gene silencing technology and use thereof |
| BR112023024384A2 (pt) | 2021-05-31 | 2024-02-15 | Rena Therapeutics Inc | Complexo de ácido nucleico ligado ao ligante |
| US11633498B2 (en) | 2021-07-09 | 2023-04-25 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| US11638761B2 (en) | 2021-07-09 | 2023-05-02 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy |
| US11969475B2 (en) | 2021-07-09 | 2024-04-30 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| JP2024528659A (ja) | 2021-07-19 | 2024-07-30 | アルナイラム ファーマシューティカルズ， インコーポレイテッド | 非原発性高シュウ酸尿症疾患または障害を有するまたは発症するリスクがある対象を治療するための方法および組成物 |
| WO2023013329A1 (ja) | 2021-08-04 | 2023-02-09 | 国立大学法人東京大学 | ヘアピン核酸組成物 |
| US20250339459A1 (en) | 2021-08-19 | 2025-11-06 | National University Corporation Tokyo Medical And Dental University | Modified heteronucleic acid containing morpholino nucleic acid |
| EP4389893A4 (en) | 2021-08-21 | 2025-09-10 | Takeda Pharmaceuticals Co | PEPTIDE-DRUG CONJUGATE BINDING HUMAN TRANSFERRIN RECEPTOR |
| JP2024532476A (ja) * | 2021-09-02 | 2024-09-05 | モレキュラー アクシオム エルエルシー | Ｎｌｒｐ３またはｎｌｒｐ１発現を調節するための組成物及び方法 |
| JP2024531728A (ja) | 2021-09-14 | 2024-08-29 | アルゴノート アールエヌエー リミテッド | 心血管疾患の処置 |
| JPWO2023042876A1 (cg-RX-API-DMAC7.html) | 2021-09-15 | 2023-03-23 | ||
| AU2022345881A1 (en) | 2021-09-20 | 2024-03-21 | Alnylam Pharmaceuticals, Inc. | Inhibin subunit beta e (inhbe) modulator compositions and methods of use thereof |
| EP4428238A1 (en) | 2021-11-02 | 2024-09-11 | Rena Therapeutics Inc. | Ligand-bound nucleic acid complex |
| CN118284695A (zh) | 2021-11-11 | 2024-07-02 | 豪夫迈·罗氏有限公司 | 用于治疗hbv的药物组合 |
| DE102021131135A1 (de) | 2021-11-26 | 2023-06-01 | Zf Cv Systems Global Gmbh | Funkkommunikationsmodul und Verfahren zum Absetzen eines Notrufs per Funkkommunikation |
| CN119095603A (zh) | 2021-12-17 | 2024-12-06 | 豪夫迈·罗氏有限公司 | 用于调节rtel1和fubp1的寡核苷酸的组合 |
| CN119213005A (zh) | 2022-03-16 | 2024-12-27 | 艾姆皮瑞克公司 | 用于提高siRNA生物利用度的GALNAC组合物 |
| TW202403044A (zh) | 2022-03-28 | 2024-01-16 | 美商安彼瑞可股份有限公司 | 經修飾之寡核苷酸 |
| EP4508090A1 (en) | 2022-04-15 | 2025-02-19 | Dyne Therapeutics, Inc. | Muscle targeting complexes and formulations for treating myotonic dystrophy |
| IL318625A (en) | 2022-07-29 | 2025-03-01 | Regeneron Pharma | Compositions and methods for transferrin receptor (TFR)-mediated delivery to brain and muscle |
| EP4581143A1 (en) | 2022-08-29 | 2025-07-09 | University of Rochester | Antisense oligonucleotide-based anti-fibrotic therapeutics |
| EP4340411A1 (en) | 2022-09-19 | 2024-03-20 | Cellnex Italia S.p.A | System for monitoring the operating state of the emergency call service into tunnels |
| EP4596694A1 (en) | 2022-09-29 | 2025-08-06 | Institute Of Science Tokyo | Nucleic acid molecule containing 5'-cyclopropylene modification |
| WO2024098061A2 (en) | 2022-11-04 | 2024-05-10 | Genkardia Inc. | Oligonucleotide-based therapeutics targeting cyclin d2 for the treatment of heart failure |
| EP4612184A1 (en) | 2022-11-04 | 2025-09-10 | Regeneron Pharmaceuticals, Inc. | Calcium voltage-gated channel auxiliary subunit gamma 1 (cacng1) binding proteins and cacng1-mediated delivery to skeletal muscle |
| US20240173426A1 (en) | 2022-11-14 | 2024-05-30 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for fibroblast growth factor receptor 3-mediated delivery to astrocytes |
| EP4669750A2 (en) | 2023-02-21 | 2025-12-31 | Vib Vzw | SYNAPTOGYRIN-3 EXPRESSION INHIBITORS |
| EP4669749A1 (en) | 2023-02-21 | 2025-12-31 | Vib Vzw | OLIGONUCLEOTIDES TO MODULATE SYNAPTOGYRIN-3 EXPRESSION |
| TW202449167A (zh) | 2023-04-26 | 2024-12-16 | 美商航海家醫療公司 | 用於治療肌肉萎縮性脊髓側索硬化症之組成物及方法 |
Family Cites Families (261)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US469863A (en) * | 1892-03-01 | John marks | ||
| US3687808A (en) | 1969-08-14 | 1972-08-29 | Univ Leland Stanford Junior | Synthetic polynucleotides |
| US4458066A (en) | 1980-02-29 | 1984-07-03 | University Patents, Inc. | Process for preparing polynucleotides |
| US4500707A (en) * | 1980-02-29 | 1985-02-19 | University Patents, Inc. | Nucleosides useful in the preparation of polynucleotides |
| US5132418A (en) | 1980-02-29 | 1992-07-21 | University Patents, Inc. | Process for preparing polynucleotides |
| US4469863A (en) | 1980-11-12 | 1984-09-04 | Ts O Paul O P | Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof |
| US4668777A (en) * | 1981-03-27 | 1987-05-26 | University Patents, Inc. | Phosphoramidite nucleoside compounds |
| US4415732A (en) | 1981-03-27 | 1983-11-15 | University Patents, Inc. | Phosphoramidite compounds and processes |
| US4973679A (en) | 1981-03-27 | 1990-11-27 | University Patents, Inc. | Process for oligonucleo tide synthesis using phosphormidite intermediates |
| US5023243A (en) * | 1981-10-23 | 1991-06-11 | Molecular Biosystems, Inc. | Oligonucleotide therapeutic agent and method of making same |
| US4476301A (en) | 1982-04-29 | 1984-10-09 | Centre National De La Recherche Scientifique | Oligonucleotides, a process for preparing the same and their application as mediators of the action of interferon |
| USRE34069E (en) | 1983-08-18 | 1992-09-15 | Biosyntech Gmbh | Process for the preparation of oligonucleotides |
| DE3329892A1 (de) * | 1983-08-18 | 1985-03-07 | Köster, Hubert, Prof. Dr., 2000 Hamburg | Verfahren zur herstellung von oligonucleotiden |
| US5118800A (en) | 1983-12-20 | 1992-06-02 | California Institute Of Technology | Oligonucleotides possessing a primary amino group in the terminal nucleotide |
| US5550111A (en) | 1984-07-11 | 1996-08-27 | Temple University-Of The Commonwealth System Of Higher Education | Dual action 2',5'-oligoadenylate antiviral derivatives and uses thereof |
| FR2567892B1 (fr) | 1984-07-19 | 1989-02-17 | Centre Nat Rech Scient | Nouveaux oligonucleotides, leur procede de preparation et leurs applications comme mediateurs dans le developpement des effets des interferons |
| US5367066A (en) | 1984-10-16 | 1994-11-22 | Chiron Corporation | Oligonucleotides with selectably cleavable and/or abasic sites |
| FR2575751B1 (fr) * | 1985-01-08 | 1987-04-03 | Pasteur Institut | Nouveaux nucleosides de derives de l'adenosine, leur preparation et leurs applications biologiques |
| US5166315A (en) | 1989-12-20 | 1992-11-24 | Anti-Gene Development Group | Sequence-specific binding polymers for duplex nucleic acids |
| US5185444A (en) | 1985-03-15 | 1993-02-09 | Anti-Gene Deveopment Group | Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages |
| US5405938A (en) | 1989-12-20 | 1995-04-11 | Anti-Gene Development Group | Sequence-specific binding polymers for duplex nucleic acids |
| US5235033A (en) | 1985-03-15 | 1993-08-10 | Anti-Gene Development Group | Alpha-morpholino ribonucleoside derivatives and polymers thereof |
| US5034506A (en) | 1985-03-15 | 1991-07-23 | Anti-Gene Development Group | Uncharged morpholino-based polymers having achiral intersubunit linkages |
| DE3788914T2 (de) * | 1986-09-08 | 1994-08-25 | Ajinomoto Kk | Verbindungen zur Spaltung von RNS an eine spezifische Position, Oligomere, verwendet bei der Herstellung dieser Verbindungen und Ausgangsprodukte für die Synthese dieser Oligomere. |
| US5264423A (en) | 1987-03-25 | 1993-11-23 | The United States Of America As Represented By The Department Of Health And Human Services | Inhibitors for replication of retroviruses and for the expression of oncogene products |
| US5276019A (en) * | 1987-03-25 | 1994-01-04 | The United States Of America As Represented By The Department Of Health And Human Services | Inhibitors for replication of retroviruses and for the expression of oncogene products |
| CA1340032C (en) | 1987-06-24 | 1998-09-08 | Jim Haralambidis | Lucleoside derivatives |
| US5712257A (en) | 1987-08-12 | 1998-01-27 | Hem Research, Inc. | Topically active compositions of mismatched dsRNAs |
| US4924624A (en) | 1987-10-22 | 1990-05-15 | Temple University-Of The Commonwealth System Of Higher Education | 2,',5'-phosphorothioate oligoadenylates and plant antiviral uses thereof |
| US5188897A (en) | 1987-10-22 | 1993-02-23 | Temple University Of The Commonwealth System Of Higher Education | Encapsulated 2',5'-phosphorothioate oligoadenylates |
| US5403711A (en) | 1987-11-30 | 1995-04-04 | University Of Iowa Research Foundation | Nucleic acid hybridization and amplification method for detection of specific sequences in which a complementary labeled nucleic acid probe is cleaved |
| EP0348458B1 (en) | 1987-11-30 | 1997-04-09 | University Of Iowa Research Foundation | Dna molecules stabilized by modifications of the 3'-terminal phosphodiester linkage and their use as nucleic acid probes and as therapeutic agents to block the expression of specifically targeted genes |
| IE61148B1 (en) | 1988-03-10 | 1994-10-05 | Ici Plc | Method of detecting nucleotide sequences |
| EP0406309A4 (en) * | 1988-03-25 | 1992-08-19 | The University Of Virginia Alumni Patents Foundation | Oligonucleotide n-alkylphosphoramidates |
| US5278302A (en) | 1988-05-26 | 1994-01-11 | University Patents, Inc. | Polynucleotide phosphorodithioates |
| US5216141A (en) | 1988-06-06 | 1993-06-01 | Benner Steven A | Oligonucleotide analogs containing sulfur linkages |
| US5175273A (en) | 1988-07-01 | 1992-12-29 | Genentech, Inc. | Nucleic acid intercalating agents |
| US5194599A (en) | 1988-09-23 | 1993-03-16 | Gilead Sciences, Inc. | Hydrogen phosphonodithioate compositions |
| US5256775A (en) | 1989-06-05 | 1993-10-26 | Gilead Sciences, Inc. | Exonuclease-resistant oligonucleotides |
| US5134066A (en) | 1989-08-29 | 1992-07-28 | Monsanto Company | Improved probes using nucleosides containing 3-dezauracil analogs |
| US5591722A (en) | 1989-09-15 | 1997-01-07 | Southern Research Institute | 2'-deoxy-4'-thioribonucleosides and their antiviral activity |
| US5721218A (en) | 1989-10-23 | 1998-02-24 | Gilead Sciences, Inc. | Oligonucleotides with inverted polarity |
| US5399676A (en) | 1989-10-23 | 1995-03-21 | Gilead Sciences | Oligonucleotides with inverted polarity |
| JPH05504552A (ja) | 1989-10-24 | 1993-07-15 | ギリアド サイエンシズ，インコーポレイテッド | ２’位が改変されたオリゴヌクレオチド |
| US5264564A (en) | 1989-10-24 | 1993-11-23 | Gilead Sciences | Oligonucleotide analogs with novel linkages |
| US5264562A (en) | 1989-10-24 | 1993-11-23 | Gilead Sciences, Inc. | Oligonucleotide analogs with novel linkages |
| US5177198A (en) * | 1989-11-30 | 1993-01-05 | University Of N.C. At Chapel Hill | Process for preparing oligoribonucleoside and oligodeoxyribonucleoside boranophosphates |
| US5130302A (en) * | 1989-12-20 | 1992-07-14 | Boron Bilogicals, Inc. | Boronated nucleoside, nucleotide and oligonucleotide compounds, compositions and methods for using same |
| US6005087A (en) | 1995-06-06 | 1999-12-21 | Isis Pharmaceuticals, Inc. | 2'-modified oligonucleotides |
| US5646265A (en) | 1990-01-11 | 1997-07-08 | Isis Pharmceuticals, Inc. | Process for the preparation of 2'-O-alkyl purine phosphoramidites |
| US5587470A (en) * | 1990-01-11 | 1996-12-24 | Isis Pharmaceuticals, Inc. | 3-deazapurines |
| US5459255A (en) | 1990-01-11 | 1995-10-17 | Isis Pharmaceuticals, Inc. | N-2 substituted purines |
| US5681941A (en) | 1990-01-11 | 1997-10-28 | Isis Pharmaceuticals, Inc. | Substituted purines and oligonucleotide cross-linking |
| US5872232A (en) * | 1990-01-11 | 1999-02-16 | Isis Pharmaceuticals Inc. | 2'-O-modified oligonucleotides |
| US5623065A (en) | 1990-08-13 | 1997-04-22 | Isis Pharmaceuticals, Inc. | Gapped 2' modified oligonucleotides |
| US5587361A (en) | 1991-10-15 | 1996-12-24 | Isis Pharmaceuticals, Inc. | Oligonucleotides having phosphorothioate linkages of high chiral purity |
| US5670633A (en) | 1990-01-11 | 1997-09-23 | Isis Pharmaceuticals, Inc. | Sugar modified oligonucleotides that detect and modulate gene expression |
| US5220007A (en) | 1990-02-15 | 1993-06-15 | The Worcester Foundation For Experimental Biology | Method of site-specific alteration of RNA and production of encoded polypeptides |
| US5149797A (en) | 1990-02-15 | 1992-09-22 | The Worcester Foundation For Experimental Biology | Method of site-specific alteration of rna and production of encoded polypeptides |
| US5321131A (en) | 1990-03-08 | 1994-06-14 | Hybridon, Inc. | Site-specific functionalization of oligodeoxynucleotides for non-radioactive labelling |
| US5470967A (en) | 1990-04-10 | 1995-11-28 | The Dupont Merck Pharmaceutical Company | Oligonucleotide analogs with sulfamate linkages |
| GB9009980D0 (en) | 1990-05-03 | 1990-06-27 | Amersham Int Plc | Phosphoramidite derivatives,their preparation and the use thereof in the incorporation of reporter groups on synthetic oligonucleotides |
| EP0745689A3 (en) | 1990-05-11 | 1996-12-11 | Microprobe Corporation | A dipstick for a nucleic acid hybridization assay |
| US5677437A (en) | 1990-07-27 | 1997-10-14 | Isis Pharmaceuticals, Inc. | Heteroatomic oligonucleoside linkages |
| US5223618A (en) | 1990-08-13 | 1993-06-29 | Isis Pharmaceuticals, Inc. | 4'-desmethyl nucleoside analog compounds |
| US5608046A (en) | 1990-07-27 | 1997-03-04 | Isis Pharmaceuticals, Inc. | Conjugated 4'-desmethyl nucleoside analog compounds |
| US5623070A (en) * | 1990-07-27 | 1997-04-22 | Isis Pharmaceuticals, Inc. | Heteroatomic oligonucleoside linkages |
| US5386023A (en) | 1990-07-27 | 1995-01-31 | Isis Pharmaceuticals | Backbone modified oligonucleotide analogs and preparation thereof through reductive coupling |
| US5541307A (en) | 1990-07-27 | 1996-07-30 | Isis Pharmaceuticals, Inc. | Backbone modified oligonucleotide analogs and solid phase synthesis thereof |
| US5602240A (en) | 1990-07-27 | 1997-02-11 | Ciba Geigy Ag. | Backbone modified oligonucleotide analogs |
| US5618704A (en) * | 1990-07-27 | 1997-04-08 | Isis Pharmacueticals, Inc. | Backbone-modified oligonucleotide analogs and preparation thereof through radical coupling |
| ATE154246T1 (de) * | 1990-07-27 | 1997-06-15 | Isis Pharmaceuticals Inc | Nuklease resistente, pyrimidin modifizierte oligonukleotide, die die gen-expression detektieren und modulieren |
| US5378825A (en) | 1990-07-27 | 1995-01-03 | Isis Pharmaceuticals, Inc. | Backbone modified oligonucleotide analogs |
| US5610289A (en) | 1990-07-27 | 1997-03-11 | Isis Pharmaceuticals, Inc. | Backbone modified oligonucleotide analogues |
| US5489677A (en) * | 1990-07-27 | 1996-02-06 | Isis Pharmaceuticals, Inc. | Oligonucleoside linkages containing adjacent oxygen and nitrogen atoms |
| FI930455A7 (fi) | 1990-08-03 | 1993-03-24 | Sanofi Sa | Yhdisteitä ja menetelmiä geeniekspression inhiboimiseksi |
| US6852536B2 (en) * | 2001-12-18 | 2005-02-08 | Isis Pharmaceuticals, Inc. | Antisense modulation of CD36L 1 expression |
| US5177196A (en) | 1990-08-16 | 1993-01-05 | Microprobe Corporation | Oligo (α-arabinofuranosyl nucleotides) and α-arabinofuranosyl precursors thereof |
| US5214134A (en) | 1990-09-12 | 1993-05-25 | Sterling Winthrop Inc. | Process of linking nucleosides with a siloxane bridge |
| US5561225A (en) | 1990-09-19 | 1996-10-01 | Southern Research Institute | Polynucleotide analogs containing sulfonate and sulfonamide internucleoside linkages |
| EP0549686A4 (en) * | 1990-09-20 | 1995-01-18 | Gilead Sciences Inc | Modified internucleoside linkages |
| US5432272A (en) * | 1990-10-09 | 1995-07-11 | Benner; Steven A. | Method for incorporating into a DNA or RNA oligonucleotide using nucleotides bearing heterocyclic bases |
| US5220006A (en) | 1990-10-23 | 1993-06-15 | The United States Of America As Represented By The Department Of Health And Human Services | Identification of a suppressor of atherogenic apolipoprotein |
| US6582908B2 (en) | 1990-12-06 | 2003-06-24 | Affymetrix, Inc. | Oligonucleotides |
| CA2098838C (en) * | 1990-12-21 | 2002-11-26 | Frances M. Sladek | Liver enriched transcription factor |
| US5672697A (en) | 1991-02-08 | 1997-09-30 | Gilead Sciences, Inc. | Nucleoside 5'-methylene phosphonates |
| US5965722A (en) * | 1991-05-21 | 1999-10-12 | Isis Pharmaceuticals, Inc. | Antisense inhibition of ras gene with chimeric and alternating oligonucleotides |
| US5578444A (en) * | 1991-06-27 | 1996-11-26 | Genelabs Technologies, Inc. | Sequence-directed DNA-binding molecules compositions and methods |
| JPH07501204A (ja) | 1991-06-28 | 1995-02-09 | マサチューセッツ インスティテュート オブ テクノロジー | 局所的オリゴヌクレオチド療法 |
| US5571799A (en) | 1991-08-12 | 1996-11-05 | Basco, Ltd. | (2'-5') oligoadenylate analogues useful as inhibitors of host-v5.-graft response |
| US5877009A (en) * | 1991-08-16 | 1999-03-02 | Trustees Of Boston University | Isolated ApoA-I gene regulatory sequence elements |
| DE4129653A1 (de) | 1991-09-06 | 1993-03-11 | Boehringer Mannheim Gmbh | Verfahren zum nachweis aehnlicher nukleinsaeuren |
| US5408038A (en) | 1991-10-09 | 1995-04-18 | The Scripps Research Institute | Nonnatural apolipoprotein B-100 peptides and apolipoprotein B-100-apolipoprotein A-I fusion peptides |
| EP0538194B1 (de) * | 1991-10-17 | 1997-06-04 | Novartis AG | Bicyclische Nukleoside, Oligonukleotide, Verfahren zu deren Herstellung und Zwischenprodukte |
| US5594121A (en) | 1991-11-07 | 1997-01-14 | Gilead Sciences, Inc. | Enhanced triple-helix and double-helix formation with oligomers containing modified purines |
| TW393513B (en) | 1991-11-26 | 2000-06-11 | Isis Pharmaceuticals Inc | Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines |
| EP0637965B1 (en) | 1991-11-26 | 2002-10-16 | Isis Pharmaceuticals, Inc. | Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines |
| US5484908A (en) * | 1991-11-26 | 1996-01-16 | Gilead Sciences, Inc. | Oligonucleotides containing 5-propynyl pyrimidines |
| US5792608A (en) | 1991-12-12 | 1998-08-11 | Gilead Sciences, Inc. | Nuclease stable and binding competent oligomers and methods for their use |
| US5359044A (en) | 1991-12-13 | 1994-10-25 | Isis Pharmaceuticals | Cyclobutyl oligonucleotide surrogates |
| JPH07502414A (ja) * | 1991-12-23 | 1995-03-16 | バイエル コーポレイション | 溶液相サンドイッチハイブリダイゼーションアッセイに用いるためのクラミジアプローブ |
| US5700922A (en) | 1991-12-24 | 1997-12-23 | Isis Pharmaceuticals, Inc. | PNA-DNA-PNA chimeric macromolecules |
| FR2687679B1 (fr) | 1992-02-05 | 1994-10-28 | Centre Nat Rech Scient | Oligothionucleotides. |
| US5633360A (en) | 1992-04-14 | 1997-05-27 | Gilead Sciences, Inc. | Oligonucleotide analogs capable of passive cell membrane permeation |
| FR2692265B1 (fr) | 1992-05-25 | 1996-11-08 | Centre Nat Rech Scient | Composes biologiquement actifs de type phosphotriesters. |
| US5434257A (en) * | 1992-06-01 | 1995-07-18 | Gilead Sciences, Inc. | Binding compentent oligomers containing unsaturated 3',5' and 2',5' linkages |
| NL9300058A (nl) * | 1992-06-18 | 1994-01-17 | Stichting Rega V Z W | 1,5-anhydrohexitol nucleoside analoga en farmaceutisch gebruik daarvan. |
| EP0577558A2 (de) | 1992-07-01 | 1994-01-05 | Ciba-Geigy Ag | Carbocyclische Nukleoside mit bicyclischen Ringen, Oligonukleotide daraus, Verfahren zu deren Herstellung, deren Verwendung und Zwischenproduckte |
| US5652355A (en) | 1992-07-23 | 1997-07-29 | Worcester Foundation For Experimental Biology | Hybrid oligonucleotide phosphorothioates |
| JPH08502723A (ja) | 1992-07-27 | 1996-03-26 | ハイブライドン インコーポレイテッド | オリゴヌクレオチド・アルキルホスホノチオエート |
| US6180403B1 (en) | 1999-10-28 | 2001-01-30 | Isis Pharmaceuticals Inc. | Antisense inhibition of tumor necrosis factor alpha converting enzyme (TACE) expression |
| WO1994014226A1 (en) | 1992-12-14 | 1994-06-23 | Honeywell Inc. | Motor system with individually controlled redundant windings |
| AU6165494A (en) | 1993-01-25 | 1994-08-15 | Hybridon, Inc. | Oligonucleotide alkylphosphonates and alkylphosphonothioates |
| US5476925A (en) | 1993-02-01 | 1995-12-19 | Northwestern University | Oligodeoxyribonucleotides including 3'-aminonucleoside-phosphoramidate linkages and terminal 3'-amino groups |
| US5434058A (en) | 1993-02-09 | 1995-07-18 | Arch Development Corporation | Apolipoprotein B MRNA editing protein compositions and methods |
| IL108340A (en) * | 1993-03-04 | 1996-10-16 | Innova Sa | Citric acid extraction |
| GB9304618D0 (en) | 1993-03-06 | 1993-04-21 | Ciba Geigy Ag | Chemical compounds |
| GB9304620D0 (en) | 1993-03-06 | 1993-04-21 | Ciba Geigy Ag | Compounds |
| EP0691968B1 (en) | 1993-03-30 | 1997-07-16 | Sanofi | Acyclic nucleoside analogs and oligonucleotide sequences containing them |
| CA2159632A1 (en) | 1993-03-31 | 1994-10-13 | Ashis Kumar Saha | Novel 5'-substituted nucleosides and oligomers produced therefrom |
| EP0691977B1 (en) | 1993-03-31 | 1997-11-26 | Sanofi | Oligonucleotides with amide linkages replacing phosphodiester linkages |
| DE4311944A1 (de) | 1993-04-10 | 1994-10-13 | Degussa | Umhüllte Natriumpercarbonatpartikel, Verfahren zu deren Herstellung und sie enthaltende Wasch-, Reinigungs- und Bleichmittelzusammensetzungen |
| FR2705099B1 (fr) | 1993-05-12 | 1995-08-04 | Centre Nat Rech Scient | Oligonucléotides phosphorothioates triesters et procédé de préparation. |
| US5502177A (en) | 1993-09-17 | 1996-03-26 | Gilead Sciences, Inc. | Pyrimidine derivatives for labeled binding partners |
| US5801154A (en) | 1993-10-18 | 1998-09-01 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of multidrug resistance-associated protein |
| US6235470B1 (en) | 1993-11-12 | 2001-05-22 | The Johns Hopkins University School Of Medicine | Detection of neoplasia by analysis of saliva |
| US5457187A (en) | 1993-12-08 | 1995-10-10 | Board Of Regents University Of Nebraska | Oligonucleotides containing 5-fluorouracil |
| US5446137B1 (en) | 1993-12-09 | 1998-10-06 | Behringwerke Ag | Oligonucleotides containing 4'-substituted nucleotides |
| ES2149962T3 (es) | 1993-12-09 | 2000-11-16 | Univ Jefferson | Compuestos y metodos para mutaciones dirigidas al sitio en celulas eucarioticas. |
| US5519134A (en) * | 1994-01-11 | 1996-05-21 | Isis Pharmaceuticals, Inc. | Pyrrolidine-containing monomers and oligomers |
| US5596091A (en) | 1994-03-18 | 1997-01-21 | The Regents Of The University Of California | Antisense oligonucleotides comprising 5-aminoalkyl pyrimidine nucleotides |
| US5627053A (en) | 1994-03-29 | 1997-05-06 | Ribozyme Pharmaceuticals, Inc. | 2'deoxy-2'-alkylnucleotide containing nucleic acid |
| US5625050A (en) | 1994-03-31 | 1997-04-29 | Amgen Inc. | Modified oligonucleotides and intermediates useful in nucleic acid therapeutics |
| US5646269A (en) | 1994-04-28 | 1997-07-08 | Gilead Sciences, Inc. | Method for oligonucleotide analog synthesis |
| US6103890A (en) | 1994-05-18 | 2000-08-15 | Ribozyme Pharmaceuticals, Inc. | Enzymatic nucleic acids that cleave C-fos |
| US5525711A (en) | 1994-05-18 | 1996-06-11 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Pteridine nucleotide analogs as fluorescent DNA probes |
| US5656612A (en) | 1994-05-31 | 1997-08-12 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of raf gene expression |
| US5485908A (en) * | 1994-07-12 | 1996-01-23 | Coin Acceptors, Inc. | Pattern recognition using artificial neural network for coin validation |
| US5618065A (en) * | 1994-07-21 | 1997-04-08 | Hitachi Metals, Ltd. | Electric welding pipe joint having a two layer outer member |
| US5597909A (en) * | 1994-08-25 | 1997-01-28 | Chiron Corporation | Polynucleotide reagents containing modified deoxyribose moieties, and associated methods of synthesis and use |
| US5792747A (en) | 1995-01-24 | 1998-08-11 | The Administrators Of The Tulane Educational Fund | Highly potent agonists of growth hormone releasing hormone |
| US5652356A (en) | 1995-08-17 | 1997-07-29 | Hybridon, Inc. | Inverted chimeric and hybrid oligonucleotides |
| KR0185334B1 (ko) | 1995-11-02 | 1999-04-01 | 김은영 | 인간 혈장 아포지단백질 비-100에 결합하는 생쥐 항체를 암호하는 씨디엔에이 |
| AU2291397A (en) | 1996-03-26 | 1997-10-17 | Glaxo Group Limited | Tumor necrosis factor alpha convertase |
| ATE232880T1 (de) | 1996-11-18 | 2003-03-15 | Takeshi Imanishi | Neue nucleotidanaloga |
| WO1998036641A1 (en) | 1997-02-20 | 1998-08-27 | The Schepens Eye Research Institute, Inc. | Control of il4 production as a therapeutic regulator of immune function |
| JP3756313B2 (ja) | 1997-03-07 | 2006-03-15 | 武 今西 | 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体 |
| US6770748B2 (en) | 1997-03-07 | 2004-08-03 | Takeshi Imanishi | Bicyclonucleoside and oligonucleotide analogue |
| US6133246A (en) | 1997-08-13 | 2000-10-17 | Isis Pharmaceuticals Inc. | Antisense oligonucleotide compositions and methods for the modulation of JNK proteins |
| US6794499B2 (en) | 1997-09-12 | 2004-09-21 | Exiqon A/S | Oligonucleotide analogues |
| EP2253639A1 (en) | 1997-09-12 | 2010-11-24 | Exiqon A/S | Bi- and tri-cyclic nucleoside, nucleotide and oligonucleoide analogues |
| GB9721240D0 (en) | 1997-10-08 | 1997-12-03 | Zeneca Ltd | Assay |
| US6156315A (en) | 1997-10-10 | 2000-12-05 | The Trustees Of Columbia University In The City Of New York | Method for inhibiting the binding of low density lipoprotein to blood vessel matrix |
| US6309844B1 (en) | 1997-10-15 | 2001-10-30 | Fujirebio Inc. | Anti-apo-B-48 monoclonal antibody, hybridoma producing the same, and method for measuring apo-B-48 using the same |
| JP2002500039A (ja) | 1998-01-08 | 2002-01-08 | アベンティス ファーマスーティカルズ プロダクツ インコーポレイテッド | 機能あるヒトリポタンパク質（ａ）を発現するトランスジェニックウサギ |
| US6238921B1 (en) | 1998-03-26 | 2001-05-29 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of human mdm2 expression |
| US6949367B1 (en) | 1998-04-03 | 2005-09-27 | Epoch Pharmaceuticals, Inc. | Modified oligonucleotides for mismatch discrimination |
| US20030228597A1 (en) | 1998-04-13 | 2003-12-11 | Cowsert Lex M. | Identification of genetic targets for modulation by oligonucleotides and generation of oligonucleotides for gene modulation |
| US6300319B1 (en) | 1998-06-16 | 2001-10-09 | Isis Pharmaceuticals, Inc. | Targeted oligonucleotide conjugates |
| US6007995A (en) | 1998-06-26 | 1999-12-28 | Isis Pharmaceuticals Inc. | Antisense inhibition of TNFR1 expression |
| EP0979869A1 (en) | 1998-08-07 | 2000-02-16 | Hoechst Marion Roussel Deutschland GmbH | Short oligonucleotides for the inhibition of VEGF expression |
| US6043352A (en) | 1998-08-07 | 2000-03-28 | Isis Pharmaceuticals, Inc. | 2'-O-Dimethylaminoethyloxyethyl-modified oligonucleotides |
| US6410323B1 (en) | 1999-08-31 | 2002-06-25 | Isis Pharmaceuticals, Inc. | Antisense modulation of human Rho family gene expression |
| US5945290A (en) | 1998-09-18 | 1999-08-31 | Isis Pharmaceuticals, Inc. | Antisense modulation of RhoA expression |
| US6172216B1 (en) | 1998-10-07 | 2001-01-09 | Isis Pharmaceuticals Inc. | Antisense modulation of BCL-X expression |
| EP1152009B2 (en) | 1999-02-12 | 2017-09-06 | Daiichi Sankyo Company, Limited | Novel nucleosides and oligonucleotide analogues |
| EP1161561B1 (en) | 1999-03-18 | 2005-12-28 | Exiqon A/S | One step sample preparation and detection of nucleic acids in complex biological samples |
| US6436640B1 (en) | 1999-03-18 | 2002-08-20 | Exiqon A/S | Use of LNA in mass spectrometry |
| US7084125B2 (en) | 1999-03-18 | 2006-08-01 | Exiqon A/S | Xylo-LNA analogues |
| EP1161554B1 (en) | 1999-03-18 | 2011-03-09 | Exiqon A/S | Detection of mutations in genes by specific lna primers |
| US20040171566A1 (en) | 1999-04-06 | 2004-09-02 | Monia Brett P. | Antisense modulation of p38 mitogen activated protein kinase expression |
| US6140124A (en) * | 1999-04-06 | 2000-10-31 | Isis Pharmaceuticals Inc. | Antisense modulation of P38 mitogen activated protein kinase expression |
| US5998148A (en) | 1999-04-08 | 1999-12-07 | Isis Pharmaceuticals Inc. | Antisense modulation of microtubule-associated protein 4 expression |
| CN102180924A (zh) | 1999-05-04 | 2011-09-14 | 桑塔里斯制药公司 | L-核糖-lna类似物 |
| US6525191B1 (en) | 1999-05-11 | 2003-02-25 | Kanda S. Ramasamy | Conformationally constrained L-nucleosides |
| US6033910A (en) | 1999-07-19 | 2000-03-07 | Isis Pharmaceuticals Inc. | Antisense inhibition of MAP kinase kinase 6 expression |
| JP4151751B2 (ja) | 1999-07-22 | 2008-09-17 | 第一三共株式会社 | 新規ビシクロヌクレオシド類縁体 |
| WO2001012789A2 (en) | 1999-08-18 | 2001-02-22 | Baylor College Of Medicine | APOLIPOPROTEIN B mRNA-SPECIFIC RIBOZYME |
| WO2001022972A2 (en) | 1999-09-25 | 2001-04-05 | University Of Iowa Research Foundation | Immunostimulatory nucleic acids |
| US20020068709A1 (en) | 1999-12-23 | 2002-06-06 | Henrik Orum | Therapeutic uses of LNA-modified oligonucleotides |
| WO2001046260A2 (en) * | 1999-12-23 | 2001-06-28 | Bristol-Myers Squibb Company | Novel immunoglobulin superfamily members apex-1, apex-2 and apex-3 and uses thereof |
| US7179796B2 (en) | 2000-01-18 | 2007-02-20 | Isis Pharmaceuticals, Inc. | Antisense modulation of PTP1B expression |
| US6602857B1 (en) * | 2000-01-18 | 2003-08-05 | Isis Pharmaceuticals, Inc. | Antisense modulation of PTP1B expression |
| US20020055479A1 (en) * | 2000-01-18 | 2002-05-09 | Cowsert Lex M. | Antisense modulation of PTP1B expression |
| US6261840B1 (en) | 2000-01-18 | 2001-07-17 | Isis Pharmaceuticals, Inc. | Antisense modulation of PTP1B expression |
| WO2001052902A1 (en) | 2000-01-24 | 2001-07-26 | Isis Pharmaceuticals, Inc. | Antisense modulation of inducible nitric oxide synthase expression |
| US20030064950A1 (en) * | 2001-02-23 | 2003-04-03 | Ntambi James M. | Methods for reducing body fat and increasing lean body mass by reducing stearoyl-CoA desaturase 1 activity |
| AU4036600A (en) | 2000-03-28 | 2001-10-08 | Isis Pharmaceuticals Inc | Alteration of cellular behavior by antisense modulation of mrna processing |
| WO2001077384A2 (de) | 2000-04-07 | 2001-10-18 | Epigenomics Ag | DETEKTION VON SNPs UND CYTOSIN-METHYLIERUNGEN |
| WO2001079555A2 (en) * | 2000-04-14 | 2001-10-25 | Millennium Pharmaceuticals, Inc. | Roles of jak/stat family members in tolerance induction |
| EP1314734A1 (en) * | 2000-08-29 | 2003-05-28 | Takeshi Imanishi | Novel nucleoside analogs and oligonucleotide derivatives containing these analogs |
| US20040024144A1 (en) * | 2000-09-14 | 2004-02-05 | Robert Solomon | Aqueous dispersions of comb copolymers and coatings produced therefrom |
| WO2002026768A2 (en) | 2000-09-29 | 2002-04-04 | Genaissance Pharmaceuticals, Inc. | Haplotypes of the por gene |
| US6426220B1 (en) | 2000-10-30 | 2002-07-30 | Isis Pharmaceuticals, Inc. | Antisense modulation of calreticulin expression |
| US20030008373A1 (en) * | 2001-04-17 | 2003-01-09 | Myriad Genetics, Incorporated | APOA1-interacting proteins and use thereof |
| JP2002355074A (ja) | 2001-01-24 | 2002-12-10 | Univ Tsukuba | 腸管出血性病原性大腸菌ｏ１５７：ｈ７に特異的な核酸分子およびポリペプチド並びにこれらの使用方法 |
| EP1239051A3 (en) | 2001-01-30 | 2004-03-17 | Aeomica, Inc. | Human posh-like protein 1 |
| US6878729B2 (en) | 2001-05-04 | 2005-04-12 | The Procter & Gamble Company | Medicinal uses of dihydropyrazoles |
| US6660737B2 (en) | 2001-05-04 | 2003-12-09 | The Procter & Gamble Company | Medicinal uses of hydrazones |
| US20030125241A1 (en) | 2001-05-18 | 2003-07-03 | Margit Wissenbach | Therapeutic uses of LNA-modified oligonucleotides in infectious diseases |
| US20050019915A1 (en) | 2001-06-21 | 2005-01-27 | Bennett C. Frank | Antisense modulation of superoxide dismutase 1, soluble expression |
| US6964950B2 (en) | 2001-07-25 | 2005-11-15 | Isis Pharmaceuticals, Inc. | Antisense modulation of C-reactive protein expression |
| US7425545B2 (en) * | 2001-07-25 | 2008-09-16 | Isis Pharmaceuticals, Inc. | Modulation of C-reactive protein expression |
| US7888324B2 (en) * | 2001-08-01 | 2011-02-15 | Genzyme Corporation | Antisense modulation of apolipoprotein B expression |
| US7407943B2 (en) * | 2001-08-01 | 2008-08-05 | Isis Pharmaceuticals, Inc. | Antisense modulation of apolipoprotein B expression |
| WO2003020739A2 (en) | 2001-09-04 | 2003-03-13 | Exiqon A/S | Novel lna compositions and uses thereof |
| US7297485B2 (en) * | 2001-10-15 | 2007-11-20 | Qiagen Gmbh | Method for nucleic acid amplification that results in low amplification bias |
| MXPA04008472A (es) | 2002-03-01 | 2005-09-20 | Ravgen Inc | Analisis rapido de variaciones en un genoma. |
| CA2480311C (en) | 2002-04-05 | 2015-01-27 | Santaris Pharma A/S | Oligomeric compounds for the modulation of hif-1alpha expression |
| US7569575B2 (en) * | 2002-05-08 | 2009-08-04 | Santaris Pharma A/S | Synthesis of locked nucleic acid derivatives |
| AU2003237875A1 (en) | 2002-05-15 | 2003-12-02 | Isis Pharmaceuticals, Inc. | Antisense modulation of apolipoprotein b expression |
| WO2003099215A2 (en) * | 2002-05-20 | 2003-12-04 | Pharmacia Corporation | Antisense modulation of glucocorticoid receptor expression |
| US7393950B2 (en) | 2002-08-29 | 2008-07-01 | Hong Kong University Of Science & Technology | Antisense oligonucleotides targeted to human CDC45 |
| US20040219565A1 (en) | 2002-10-21 | 2004-11-04 | Sakari Kauppinen | Oligonucleotides useful for detecting and analyzing nucleic acids of interest |
| AU2003287505A1 (en) | 2002-11-05 | 2004-06-03 | Isis Pharmaceuticals, Inc. | Chimeric oligomeric compounds and their use in gene modulation |
| AU2003295389A1 (en) | 2002-11-05 | 2004-06-03 | Isis Pharmaceuticals, Inc. | Conjugated oligomeric compounds and their use in gene modulation |
| AU2003291753B2 (en) | 2002-11-05 | 2010-07-08 | Isis Pharmaceuticals, Inc. | Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation |
| US20060009410A1 (en) | 2002-11-13 | 2006-01-12 | Crooke Rosanne M | Effects of apolipoprotein B inhibition on gene expression profiles in animals |
| WO2004044181A2 (en) * | 2002-11-13 | 2004-05-27 | Isis Pharmaceuticals, Inc. | Antisense modulation of apolipoprotein b expression |
| US7511131B2 (en) * | 2002-11-13 | 2009-03-31 | Genzyme Corporation | Antisense modulation of apolipoprotein B expression |
| US8090542B2 (en) | 2002-11-14 | 2012-01-03 | Dharmacon Inc. | Functional and hyperfunctional siRNA |
| DK1569661T3 (da) | 2002-11-18 | 2010-01-11 | Santaris Pharma As | Antisense design |
| CN101260130A (zh) | 2003-01-03 | 2008-09-10 | 布里斯托尔-迈尔斯斯奎布公司 | 制备c-芳基葡糖苷sglt2抑制剂的方法 |
| US20040185559A1 (en) | 2003-03-21 | 2004-09-23 | Isis Pharmaceuticals Inc. | Modulation of diacylglycerol acyltransferase 1 expression |
| US7598227B2 (en) * | 2003-04-16 | 2009-10-06 | Isis Pharmaceuticals Inc. | Modulation of apolipoprotein C-III expression |
| JP4597976B2 (ja) | 2003-04-17 | 2010-12-15 | アルナイラム ファーマシューティカルズ インコーポレイテッド | 修飾ｉＲＮＡ剤 |
| US7399853B2 (en) | 2003-04-28 | 2008-07-15 | Isis Pharmaceuticals | Modulation of glucagon receptor expression |
| US7750142B2 (en) * | 2003-04-28 | 2010-07-06 | Isis Pharmaceuticals, Inc. | Modulation of glucagon receptor expression |
| BRPI0411170A (pt) | 2003-05-12 | 2006-07-18 | Union Carbide Chem Plastic | processo de polimerização de olefinas em fase gasosa |
| JP2005060664A (ja) | 2003-07-31 | 2005-03-10 | Asahi Glass Co Ltd | 含フッ素化合物、含フッ素ポリマーとその製造方法およびそれを含むレジスト組成物 |
| WO2005013901A2 (en) * | 2003-07-31 | 2005-02-17 | Isis Pharmaceuticals, Inc. | Oligomeric compounds and compositions for use in modulation of small non-coding rnas |
| US7825235B2 (en) * | 2003-08-18 | 2010-11-02 | Isis Pharmaceuticals, Inc. | Modulation of diacylglycerol acyltransferase 2 expression |
| DK1661905T3 (da) | 2003-08-28 | 2012-07-23 | Takeshi Imanishi | Hidtil ukendte syntetiske nukleinsyrer af N-O-krydsbindingstype |
| US20050053981A1 (en) * | 2003-09-09 | 2005-03-10 | Swayze Eric E. | Gapped oligomeric compounds having linked bicyclic sugar moieties at the termini |
| US20050074801A1 (en) | 2003-09-09 | 2005-04-07 | Monia Brett P. | Chimeric oligomeric compounds comprising alternating regions of northern and southern conformational geometry |
| WO2005027962A1 (en) * | 2003-09-18 | 2005-03-31 | Isis Pharmaceuticals, Inc. | 4’-thionucleosides and oligomeric compounds |
| US8258105B2 (en) | 2003-10-07 | 2012-09-04 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotides optimized for kidney targeting |
| US20050191653A1 (en) | 2003-11-03 | 2005-09-01 | Freier Susan M. | Modulation of SGLT2 expression |
| DK2708541T3 (en) | 2003-11-13 | 2015-02-23 | Isis Pharmaceuticals Inc | 5,6-dihydroxy-isoindole derivatives as linkers for oligomeric solid phase synthesis |
| WO2005061710A1 (en) | 2003-12-23 | 2005-07-07 | Santaris Pharma A/S | Oligomeric compounds for the modulation of bcl-2 |
| WO2005071080A2 (en) * | 2004-01-20 | 2005-08-04 | Isis Pharmaceuticals, Inc. | Modulation of glucocorticoid receptor expression |
| US20050287558A1 (en) | 2004-05-05 | 2005-12-29 | Crooke Rosanne M | SNPs of apolipoprotein B and modulation of their expression |
| US8394947B2 (en) * | 2004-06-03 | 2013-03-12 | Isis Pharmaceuticals, Inc. | Positionally modified siRNA constructs |
| JP2008501694A (ja) | 2004-06-03 | 2008-01-24 | アイシス ファーマシューティカルズ、インク． | 遺伝子調節の使用のために個別に修飾された鎖を有する二本鎖組成物 |
| ATE510914T1 (de) * | 2004-07-02 | 2011-06-15 | Avi Biopharma Inc | Antisinn antibakterielle verfahren und verbindungen |
| DK1786472T3 (da) * | 2004-08-10 | 2013-04-15 | Genzyme Corp | Antisense-modulering af apolipoprotein B-ekspression |
| EP1799859B1 (en) | 2004-09-17 | 2014-07-02 | Isis Pharmaceuticals, Inc. | Enhanced antisense oligonucleotides |
| AR051446A1 (es) * | 2004-09-23 | 2007-01-17 | Bristol Myers Squibb Co | Glucosidos de c-arilo como inhibidores selectivos de transportadores de glucosa (sglt2) |
| MX2007005558A (es) | 2004-11-09 | 2008-01-31 | Santaris Pharma As | Oligonucleotidos de lna potentes para la inhibicion dela expresion de hif-1a. |
| KR20070095882A (ko) | 2004-11-09 | 2007-10-01 | 산타리스 팔마 에이/에스 | Ｌｎａ 올리고뉴클레오티드 및 암의 치료 |
| EA200800823A1 (ru) * | 2005-09-15 | 2008-10-30 | Сантарис Фарма А/С | Соединения-антагонисты рнк для ингибирования экспрессии аро-в100 |
| US20070087987A1 (en) | 2005-09-19 | 2007-04-19 | Monia Brett P | Modulation of glucagon receptor expression |
| CN101313066A (zh) | 2005-09-19 | 2008-11-26 | 强生医药研究及开发有限责任公司 | 糖皮质激素受体表达的调节 |
| CN102908630B (zh) | 2006-01-27 | 2014-11-19 | Isis制药公司 | 6-修饰的双环核酸类似物 |
| EP2007889A2 (en) | 2006-04-03 | 2008-12-31 | Santaris Pharma A/S | Pharmaceutical compositions comprising anti-mirna antisense oligonucleotides |
| US20070238698A1 (en) * | 2006-04-07 | 2007-10-11 | Hsien-Chih Lin | Method for manufacturing drinking water having chitosan |
| US20090292006A1 (en) | 2006-05-05 | 2009-11-26 | Sanjay Bhanot | Compounds and methods for modulating expression of dgat2 |
| JP2007311707A (ja) * | 2006-05-22 | 2007-11-29 | Ushio Inc | 紫外線発光素子パッケージ |
| JP2010505432A (ja) | 2006-10-09 | 2010-02-25 | サンタリス ファーマ アー／エス | Ｐｃｓｋ９を調節するためのｒｎａアンタゴニスト化合物 |
| WO2008049085A1 (en) | 2006-10-18 | 2008-04-24 | Isis Pharmaceuticals, Inc. | Antisense compounds |
| JP2010522245A (ja) | 2007-03-24 | 2010-07-01 | ゲンザイム コーポレイション | ヒトアポリポタンパク質ｂと相補的なアンチセンスオリゴヌクレオチドの投与 |
-
2007
- 2007-05-07 US US12/299,605 patent/US20090292006A1/en not_active Abandoned
- 2007-05-07 EP EP07811873.4A patent/EP2015758B1/en not_active Revoked
- 2007-05-07 DK DK07811873.4T patent/DK2015758T3/da active
- 2007-05-07 CN CN201310168425.9A patent/CN103554205A/zh active Pending
- 2007-05-07 EP EP07811878.3A patent/EP2019692B1/en not_active Not-in-force
- 2007-05-07 US US12/299,583 patent/US8372967B2/en not_active Expired - Fee Related
- 2007-05-07 AU AU2007257094A patent/AU2007257094B2/en not_active Ceased
- 2007-05-07 JP JP2009510136A patent/JP2009536039A/ja active Pending
- 2007-05-07 EP EP07811874A patent/EP2023939B1/en not_active Revoked
- 2007-05-07 ES ES07811873.4T patent/ES2471978T3/es active Active
- 2007-05-07 US US12/299,607 patent/US8586554B2/en not_active Expired - Fee Related
- 2007-05-07 CA CA2651309A patent/CA2651309C/en active Active
- 2007-05-07 JP JP2009510134A patent/JP5372745B2/ja not_active Expired - Fee Related
- 2007-05-07 US US12/299,609 patent/US8188059B2/en not_active Expired - Fee Related
- 2007-05-07 EP EP11176633A patent/EP2397551A1/en not_active Withdrawn
- 2007-05-07 WO PCT/US2007/068401 patent/WO2007146511A2/en not_active Ceased
- 2007-05-07 AU AU2007253909A patent/AU2007253909B2/en not_active Ceased
- 2007-05-07 AT AT07811872T patent/ATE514777T1/de not_active IP Right Cessation
- 2007-05-07 WO PCT/US2007/068403 patent/WO2007131238A2/en not_active Ceased
- 2007-05-07 EP EP11160534A patent/EP2363482A1/en not_active Withdrawn
- 2007-05-07 ES ES07811874T patent/ES2386578T3/es active Active
- 2007-05-07 DK DK07811878.3T patent/DK2019692T3/da active
- 2007-05-07 EP EP12174128A patent/EP2505646A1/en not_active Withdrawn
- 2007-05-07 US US12/299,572 patent/US8143230B2/en not_active Expired - Fee Related
- 2007-05-07 US US12/299,768 patent/US20090326042A1/en not_active Abandoned
- 2007-05-07 BR BRPI0711429-0A patent/BRPI0711429A2/pt not_active IP Right Cessation
- 2007-05-07 EP EP07811872A patent/EP2021472B1/en not_active Revoked
- 2007-05-07 JP JP2009510130A patent/JP5731115B2/ja active Active
- 2007-05-07 EP EP11160528.3A patent/EP2363481B1/en not_active Revoked
- 2007-05-07 JP JP2009510131A patent/JP5825754B2/ja active Active
- 2007-05-07 WO PCT/US2007/068406 patent/WO2007143316A2/en not_active Ceased
- 2007-05-07 WO PCT/US2007/068415 patent/WO2007136989A2/en not_active Ceased
- 2007-05-07 AU AU2007258117A patent/AU2007258117B2/en active Active
- 2007-05-07 US US12/299,611 patent/US20090326041A1/en not_active Abandoned
- 2007-05-07 DK DK11160528.3T patent/DK2363481T3/en active
- 2007-05-07 WO PCT/US2007/068402 patent/WO2007131237A2/en not_active Ceased
- 2007-05-07 US US12/299,764 patent/US8673871B2/en active Active
- 2007-05-07 WO PCT/US2007/068408 patent/WO2007143317A2/en not_active Ceased
- 2007-05-07 DK DK07811872.6T patent/DK2021472T3/da active
- 2007-05-07 US US11/745,429 patent/US9045754B2/en active Active
- 2007-05-07 CA CA002651042A patent/CA2651042A1/en not_active Abandoned
- 2007-05-07 EP EP07811875A patent/EP2023940B1/en not_active Not-in-force
- 2007-05-07 WO PCT/US2007/068412 patent/WO2007134014A2/en not_active Ceased
- 2007-05-07 AT AT07811875T patent/ATE513912T1/de not_active IP Right Cessation
- 2007-05-07 MX MX2008014100A patent/MX2008014100A/es active IP Right Grant
- 2007-05-07 AU AU2007257093A patent/AU2007257093A1/en not_active Abandoned
- 2007-05-07 PT PT78118734T patent/PT2015758E/pt unknown
- 2007-05-07 DK DK11189591.8T patent/DK2458006T3/en active
- 2007-05-07 WO PCT/US2007/068410 patent/WO2007136988A2/en not_active Ceased
- 2007-05-07 EP EP11189591.8A patent/EP2458006B1/en active Active
- 2007-05-07 CA CA3044969A patent/CA3044969A1/en not_active Abandoned
- 2007-05-07 WO PCT/US2007/068404 patent/WO2007143315A2/en not_active Ceased
- 2007-05-07 KR KR1020087029617A patent/KR101441700B1/ko active Active
- 2007-05-07 JP JP2009510132A patent/JP2009536222A/ja active Pending
-
2008
- 2008-11-10 NO NO20084738A patent/NO20084738L/no not_active Application Discontinuation
-
2010
- 2010-09-15 US US12/883,049 patent/US8362232B2/en not_active Expired - Fee Related
-
2012
- 2012-04-27 US US13/457,960 patent/US20120208864A1/en not_active Abandoned
- 2012-10-26 US US13/662,263 patent/US8969316B2/en not_active Expired - Fee Related
-
2013
- 2013-09-05 JP JP2013184285A patent/JP2014033674A/ja active Pending
-
2014
- 2014-03-17 US US14/216,600 patent/US20150057329A1/en not_active Abandoned
-
2015
- 2015-04-28 US US14/698,554 patent/US9617540B2/en active Active
- 2015-12-21 JP JP2015248195A patent/JP6272290B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2015758T3 (da) | Forbindelser og fremgangsmåder til modulering af ekspression af apob | |
| EP2079842A4 (en) | GENERATING RECOMBINANT DNA BY SEQUENCING AND LIGATION-INDEPENDENT CLONING | |
| EP1569695A4 (en) | ANTISENSE MODULATION OF APOLIPOPROTEIN B EXPRESSION | |
| CY1119601T1 (el) | Προαγωγεις αποπτωσης | |
| NO20081884L (no) | Modulasjon av glukagonreseptorekspresjon | |
| DK2092065T3 (da) | Antisense-forbindelser | |
| DK1250455T3 (da) | Antisense-inhibering af PTP1B-ekspression | |
| EP1633302A4 (en) | MODULATION OF APOLIPOPROTEIN (A) EXPRESSION | |
| CY1116385T1 (el) | Αντινοηματικη διαμορφωση της εκφρασης της απολιποπρωτεινης β | |
| EP1417351A4 (en) | ANTISENSE MODULATION OF THE EXPRESSION OF APOLIPOPROTEIN (A) | |
| EA200900154A1 (ru) | Фосфинатные соединения (варианты), фармацевтическая композиция на их основе, способ лечения вирусного гепатита с с ее помощью, терапевтическое средство на их основе и названные соединения для изготовления лекарства от вирусного гепатита с | |
| EP1648910A4 (en) | ANTISENSE MODULATION OF THE EXPRESSION OF STEAROYL COA DESATURASE | |
| EP2527442A3 (en) | Compounds and methods for modulating gene expression | |
| EP1390388A4 (en) | ANTISENSE MODULATION OF THE EXPRESSION OF THE INTERFERON GAMMA RECEPTOR 1 | |
| BR0313550A (pt) | modulação "antisense" da expressão de sintetase 1 de acil-coa | |
| TW200716749A (en) | Interferon-beta gene therapy using an improved, regulated expression system | |
| EP1373291A4 (en) | ANTISENSE MODULATION OF RECQL4 EXPRESSION | |
| UY29543A1 (es) | Terapia génica de interferon-beta usando un sistema mejorado de expresión regulada | |
| ITBS20030110A1 (it) | Siringa monouso per odontoiatria. | |
| IT1318701B1 (it) | Siringa monouso per iniezioni. | |
| CY1114168T1 (el) | Αντιπληροφοριακη διαμορφωση της εκφρασης της απολιποπρωτεϊνης β |